IIB 

115TH CONGRESS 

2D SESSION H. R. 5925 

IN THE SENATE OF THE UNITED STATES 

JUNE 21, 2018 

Received; read twice and referred to the Committee on the Judiciary 

AN ACT 

To codify provisions relating to the Office of National Drug 

Control, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


sradovich on DSK3GMQ082PROD with BILLS
2 

HR 5925 RFS 

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Coordinated Response 

3 through Interagency Strategy and Information Sharing 

4 Act’’ or the ‘‘CRISIS Act’’. 

5 SEC. 2. OFFICE OF NATIONAL DRUG CONTROL. 

6 (a) REDESIGNATION.—The Office of National Drug 

7 Control Policy shall be known as the ‘‘Office of National 

8 Drug Control’’. 

9 (b) REFERENCES.—Any reference in any other Fed10 eral law, Executive order, rule, regulation, or delegation 

11 of authority, or any document of or relating to the Office 

12 of National Drug Control Policy is deemed to refer to the 

13 Office of National Drug Control. 

14 (c) CODIFICATION.—Subtitle I of title 31, United 

15 States Code, is amended by adding at the end the fol16 lowing new chapter: 

17 ‘‘CHAPTER 10—OFFICE OF NATIONAL 

18 DRUG CONTROL 

‘‘SUBCHAPTER I—OFFICE

‘‘1001. Definitions. 

‘‘1002. Office of National Drug Control. 

‘‘1003. Administration of the Office. 

‘‘1004. National drug control program budget. 

‘‘1005. National drug control strategy. 

‘‘1006. Development of an annual national drug control assessment. 

‘‘1007. Monitoring and evaluation of national drug control program. 

‘‘1008. Coordination and oversight of the national drug control program. 

‘‘1009. Emerging threats task force, plan, campaign. 

‘‘1010. National and international coordination. 

‘‘1011. Interdiction. 

‘‘1012. Treatment coordinator. 

‘‘1013. Critical information coordination. 

‘‘1014. Authorization of appropriations. 


sradovich on DSK3GMQ082PROD with BILLS
3 

HR 5925 RFS 

‘‘SUBCHAPTER II—DRUG-FREE COMMUNITIES SUPPORT PROGRAM

‘‘1021. Establishment of drug-free communities support program. 

‘‘1022. Program authorization. 

‘‘1023. Information collection and dissemination with respect to grant recipients. 

‘‘1024. Technical assistance and training. 

‘‘1025. Supplemental grants for coalition mentoring activities. 

‘‘1026. Authorization for National Community Antidrug Coalition Institute. 

‘‘1027. Definitions. 

‘‘1028. Drug–free communities reauthorization. 

1 ‘‘SUBCHAPTER I—OFFICE 

2 ‘‘§ 1001. Definitions 

3 ‘‘In this chapter: 

4 ‘‘(1) AGENCY.—The term ‘agency’ has the 

5 meaning given the term ‘executive agency’ in section 

6 102. 

7 ‘‘(2) APPROPRIATE CONGRESSIONAL COMMIT8 TEES.— 

9 ‘‘(A) IN GENERAL.—The term ‘appropriate 

10 congressional committees’ means— 

11 ‘‘(i) the Committee on the Judiciary, 

12 the Committee on Appropriations, the 

13 Committee on Health, Education, Labor, 

14 and Pensions, and the Caucus on Inter15 national Narcotics Control of the Senate; 

16 and 

17 ‘‘(ii) the Committee on Oversight and 

18 Government Reform, the Committee on the 

19 Judiciary, the Committee on Energy and 


sradovich on DSK3GMQ082PROD with BILLS
4 

HR 5925 RFS 

1 Commerce, and the Committee on Appro2 priations of the House of Representatives. 

3 ‘‘(B) SUBMISSION TO CONGRESS.—Any 

4 submission to Congress shall mean submission 

5 to the appropriate congressional committees. 

6 ‘‘(3) DEMAND REDUCTION.—The term ‘demand 

7 reduction’ means any activity conducted by a Na8 tional Drug Control Program Agency, other than an 

9 enforcement activity, that is intended to reduce or 

10 prevent the use of drugs or support or provide treat11 ment and recovery efforts, including— 

12 ‘‘(A) education about the dangers of illicit 

13 drug use; 

14 ‘‘(B) services, programs, or strategies to 

15 prevent substance use disorder, including evi16 dence-based education campaigns, community17 based prevention programs, collection and dis18 posal of unused prescription drugs, and services 

19 to at-risk populations to prevent or delay initial 

20 use of an illicit drug; 

21 ‘‘(C) substance use disorder treatment; 

22 ‘‘(D) illicit drug use research; 

23 ‘‘(E) drug-free workplace programs; 

24 ‘‘(F) drug testing, including the testing of 

25 employees; 


sradovich on DSK3GMQ082PROD with BILLS
5 

HR 5925 RFS 

1 ‘‘(G) interventions for illicit drug use and 

2 dependence; 

3 ‘‘(H) expanding availability of access to 

4 health care services for the treatment of sub5 stance use disorders; 

6 ‘‘(I) international drug control coordina7 tion and cooperation with respect to activities 

8 described in this paragraph; 

9 ‘‘(J) pre- and post-arrest criminal justice 

10 interventions such as diversion programs, drug 

11 courts, and the provision of evidence-based 

12 treatment to individuals with substance use dis13 orders who are arrested or under some form of 

14 criminal justice supervision, including medica15 tion assisted treatment; 

16 ‘‘(K) other coordinated and joint initiatives 

17 among Federal, State, local, and Tribal agen18 cies to promote comprehensive drug control 

19 strategies designed to reduce the demand for, 

20 and the availability of, illegal drugs; 

21 ‘‘(L) international illicit drug use edu22 cation, prevention, treatment, recovery, re23 search, rehabilitation activities, and interven24 tions for illicit drug use and dependence; and 


sradovich on DSK3GMQ082PROD with BILLS
6 

HR 5925 RFS 

1 ‘‘(M) research related to any of the activi2 ties described in this paragraph. 

3 ‘‘(4) DIRECTOR.—The term ‘Director’ means 

4 the Director of the Office of National Drug Control. 

5 ‘‘(5) DRUG.—The term ‘drug’ has the meaning 

6 given the term ‘controlled substance’ in section 

7 102(6) of the Controlled Substances Act (21 U.S.C. 

8 802(6)). 

9 ‘‘(6) DRUG CONTROL.—The term ‘drug control’ 

10 means any activity conducted by a National Drug 

11 Control Program Agency involving supply reduction 

12 or demand reduction. 

13 ‘‘(7) EMERGING DRUG THREAT.—The term 

14 ‘emerging drug threat’ means the occurrence of a 

15 new and growing trend in the use of an illicit drug 

16 or class of drugs, including rapid expansion in the 

17 supply of or demand for such drug. 

18 ‘‘(8) ILLICIT DRUG USE; ILLICIT DRUGS; ILLE19 GAL DRUGS.—The terms ‘illicit drug use’, ‘illicit 

20 drugs’, and ‘illegal drugs’ include the illegal or illicit 

21 use of prescription drugs. 

22 ‘‘(9) LAW ENFORCEMENT.—The term ‘law en23 forcement’ or ‘drug law enforcement’ means all ef24 forts by a Federal, State, local, or Tribal govern25 ment agency to enforce the drug laws of the United 


sradovich on DSK3GMQ082PROD with BILLS
7 

HR 5925 RFS 

1 States or any State, including investigation, arrest, 

2 prosecution, and incarceration or other punishments 

3 or penalties. 

4 ‘‘(10) NATIONAL DRUG CONTROL PROGRAM.— 

5 The term ‘National Drug Control Program’ means 

6 programs, policies, and activities undertaken by Na7 tional Drug Control Program Agencies pursuant to 

8 the responsibilities of such agencies under the Na9 tional Drug Control Strategy, including any activi10 ties involving supply reduction, demand reduction, or 

11 State, local, and Tribal affairs. 

12 ‘‘(11) NATIONAL DRUG CONTROL PROGRAM

13 AGENCY.—The term ‘National Drug Control Pro14 gram Agency’ means any agency (or bureau, office, 

15 independent agency, board, division, commission, 

16 subdivision, unit, or other component thereof) that is 

17 responsible for implementing any aspect of the Na18 tional Drug Control Strategy, including any agency 

19 that receives Federal funds to implement any aspect 

20 of the National Drug Control Strategy, but does not 

21 include any agency that receives funds for drug con22 trol activity solely under the National Intelligence 

23 Program or the Military Intelligence Program. 

24 ‘‘(12) NATIONAL DRUG CONTROL STRATEGY; 

25 STRATEGY.—The term ‘National Drug Control 


sradovich on DSK3GMQ082PROD with BILLS
8 

HR 5925 RFS 

1 Strategy’ or ‘Strategy’ means the strategy developed 

2 and submitted to Congress under section 1005. 

3 ‘‘(13) NONPROFIT ORGANIZATION.—The term 

4 ‘nonprofit organization’ means an organization that 

5 is described in section 501(c)(3) of the Internal Rev6 enue Code of 1986 and exempt from tax under sec7 tion 501(a) of such Code. 

8 ‘‘(14) OFFICE.—The term ‘Office’ means the 

9 Office of National Drug Control. 

10 ‘‘(15) STATE, LOCAL, AND TRIBAL AFFAIRS.— 

11 The term ‘State, local, and Tribal affairs’ means do12 mestic activities conducted by a National Drug Con13 trol Program Agency that are intended to reduce the 

14 availability and use of illegal drugs, including— 

15 ‘‘(A) coordination and enhancement of 

16 Federal, State, local, and Tribal law enforce17 ment drug control efforts; 

18 ‘‘(B) coordination and enhancement of ef19 forts among National Drug Control Program 

20 Agencies and State, local, and Tribal demand 

21 reduction and supply reduction agencies; 

22 ‘‘(C) coordination and enhancement of 

23 Federal, State, local, and Tribal law enforce24 ment initiatives to gather, analyze, and dissemi25 nate information and law enforcement intelVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
9 

HR 5925 RFS 

1 ligence relating to drug control among domestic 

2 law enforcement agencies; and 

3 ‘‘(D) other coordinated and joint initiatives 

4 among Federal, State, local, and Tribal agen5 cies to promote comprehensive drug control 

6 strategies designed to reduce the demand for, 

7 and the availability of, illegal drugs. 

8 ‘‘(16) SUBSTANCE USE DISORDER TREAT9 MENT.—The term ‘substance use disorder treat10 ment’ means an evidence-based, professionally di11 rected, deliberate, and planned regimen including 

12 evaluation, observation, medical monitoring, and re13 habilitative services and interventions such as 

14 pharmacotherapy, behavioral therapy, and individual 

15 and group counseling, on an inpatient or outpatient 

16 basis, to help patients with substance use disorder 

17 reach recovery. 

18 ‘‘(17) SUPPLY REDUCTION.—The term ‘supply 

19 reduction’ means any activity or program conducted 

20 by a National Drug Control Program Agency that is 

21 intended to reduce the availability or use of illegal 

22 drugs in the United States or abroad, including— 

23 ‘‘(A) law enforcement outside the United 

24 States; 

25 ‘‘(B) domestic law enforcement; 


sradovich on DSK3GMQ082PROD with BILLS
10 

HR 5925 RFS 

1 ‘‘(C) source country programs, including 

2 economic development programs primarily in3 tended to reduce the production or trafficking 

4 of illicit drugs; 

5 ‘‘(D) activities to control international traf6 ficking in, and availability of, illegal drugs, in7 cluding— 

8 ‘‘(i) accurate assessment and moni9 toring of international drug production and 

10 interdiction programs and policies; and 

11 ‘‘(ii) coordination and promotion of 

12 compliance with international treaties re13 lating to the production, transportation, or 

14 interdiction of illegal drugs; 

15 ‘‘(E) activities to conduct and promote 

16 international law enforcement programs and 

17 policies to reduce the supply of drugs; 

18 ‘‘(F) activities to facilitate and enhance the 

19 sharing of domestic and foreign intelligence in20 formation among National Drug Control Pro21 gram Agencies, relating to the production and 

22 trafficking of drugs in the United States and in 

23 foreign countries; 

24 ‘‘(G) activities to prevent the diversion of 

25 drugs for their illicit use; and 


sradovich on DSK3GMQ082PROD with BILLS
11 

HR 5925 RFS 

1 ‘‘(H) research related to any of the activi2 ties described in this paragraph. 

3 ‘‘§ 1002. Office of National Drug Control 

4 ‘‘(a) ESTABLISHMENT OF OFFICE.—There is estab5 lished in the Executive Office of the President an Office 

6 of National Drug Control, which shall— 

7 ‘‘(1) lead the national drug control effort, in8 cluding coordinating with Nation Drug Control Pro9 gram Agencies; 

10 ‘‘(2) coordinate and oversee the implementation 

11 of the national drug control policy, including the Na12 tional Drug Control Strategy; 

13 ‘‘(3) assess and certify the adequacy of Na14 tional Drug Control Programs and the budget for 

15 those programs; 

16 ‘‘(4) monitor and evaluate the effectiveness of 

17 national drug control policy efforts, including the 

18 National Drug Control Program Agencies’ pro19 grams, by developing and applying specific goals and 

20 performance measurements and tracking program21 level spending; 

22 ‘‘(5) identify and respond to emerging drug 

23 threats related to illicit drug use; 


sradovich on DSK3GMQ082PROD with BILLS
12 

HR 5925 RFS 

1 ‘‘(6) administer and evaluate grant programs in 

2 furtherance of the National Drug Control Strategy; 

3 and 

4 ‘‘(7) facilitate broad-scale information sharing 

5 and data standardization among Federal, State, and 

6 local entities to support the national drug control ef7 forts. 

8 ‘‘(b) DIRECTOR OF NATIONAL DRUG CONTROL AND

9 DEPUTY DIRECTOR.— 

10 ‘‘(1) DIRECTOR.— 

11 ‘‘(A) IN GENERAL.—There shall be at the 

12 head of the Office a Director who shall hold the 

13 same rank and status as the head of an execu14 tive department listed in section 101 of title 5. 

15 ‘‘(B) APPOINTMENT.—The Director shall 

16 be appointed by the President, by and with the 

17 advice and consent of the Senate, and shall 

18 serve at the pleasure of the President. 

19 ‘‘(2) DEPUTY DIRECTOR.— 

20 ‘‘(A) IN GENERAL.—There shall be a Dep21 uty Director who shall report directly to the Di22 rector, be appointed by the President, and serve 

23 at the pleasure of the President. 

24 ‘‘(B) RESPONSIBILITIES.—The Deputy Di25 rector shall— 


sradovich on DSK3GMQ082PROD with BILLS
13 

HR 5925 RFS 

1 ‘‘(i) carry out the responsibilities dele2 gated by the Director; and 

3 ‘‘(ii) be responsible for effectively co4 ordinating with the each Coordinator es5 tablished under this chapter. 

6 ‘‘(c) RESPONSIBILITIES.— 

7 ‘‘(1) POLICIES, GOALS, OBJECTIVES, AND PRI8 ORITIES.—The Director shall assist the President in 

9 directing national drug control efforts, including es10 tablishing policies, goals, objectives, and priorities 

11 for the National Drug Control Program that are 

12 based on evidence-based research. 

13 ‘‘(2) CONSULTATION.—To formulate the Na14 tional Drug Control policies, goals, objectives, and 

15 priorities, the Director— 

16 ‘‘(A) shall consult with— 

17 ‘‘(i) State and local governments; 

18 ‘‘(ii) National Drug Control Program 

19 Agencies; 

20 ‘‘(iii) each committee, working group, 

21 council, or other entity established under 

22 this chapter, as appropriate; 

23 ‘‘(iv) the public; 

24 ‘‘(v) appropriate congressional com25 mittees; and 


sradovich on DSK3GMQ082PROD with BILLS
14 

HR 5925 RFS 

1 ‘‘(vi) any other person in the discre2 tion of the Director; and 

3 ‘‘(B) may— 

4 ‘‘(i) establish advisory councils; 

5 ‘‘(ii) acquire data from agencies; and 

6 ‘‘(iii) request data from any other en7 tity. 

8 ‘‘§ 1003. Administration of the Office 

9 ‘‘(a) EMPLOYMENT.— 

10 ‘‘(1) AUTHORITY OF THE DIRECTOR.—The Di11 rector may select, appoint, employ, and fix com12 pensation of such officers and employees of the Of13 fice as may be necessary to carry out the functions 

14 of the Office under this chapter. 

15 ‘‘(2) PROHIBITIONS.— 

16 ‘‘(A) GENERALLY.—No person shall serve 

17 as Director or Deputy Director while serving in 

18 any other position in the Federal Government. 

19 ‘‘(B) PROHIBITION ON POLITICAL CAM20 PAIGNING.—Any officer or employee of the Of21 fice who is appointed to that position by the 

22 President, by and with the advice and consent 

23 of the Senate, may not participate in Federal 

24 election campaign activities, except that such 

25 officer or employee is not prohibited by this 


sradovich on DSK3GMQ082PROD with BILLS
15 

HR 5925 RFS 

1 subparagraph from making contributions to in2 dividual candidates. 

3 ‘‘(b) PROHIBITION ON THE USE OF FUNDS FOR PO4 LITICAL CAMPAIGNS OR BALLOT INITIATIVES.—No funds 

5 authorized under this chapter may be obligated for the 

6 purpose of influencing any Federal, State, or local election 

7 or ballot initiative. 

8 ‘‘(c) PERSONNEL DETAILED TO OFFICE.— 

9 ‘‘(1) EVALUATIONS.—Notwithstanding any pro10 vision of chapter 43 of title 5, the Director shall per11 form the evaluation of the performance of any em12 ployee detailed to the Office for purposes of the ap13 plicable performance appraisal system established 

14 under such chapter for any rating period, or part 

15 thereof, that such employee is detailed to the Office. 

16 ‘‘(2) COMPENSATION.— 

17 ‘‘(A) BONUS PAYMENTS.—Subject to the 

18 availability of appropriations, the Director may 

19 provide periodic bonus payments to any em20 ployee detailed to the Office. 

21 ‘‘(B) RESTRICTIONS.—An amount paid 

22 under this paragraph to an employee for any 

23 period— 


sradovich on DSK3GMQ082PROD with BILLS
16 

HR 5925 RFS 

1 ‘‘(i) shall not be greater than 20 per2 cent of the basic pay paid or payable to 

3 such employee for such period; and 

4 ‘‘(ii) shall be in addition to the basic 

5 pay of such employee. 

6 ‘‘(C) AGGREGATE AMOUNT.—The aggre7 gate amount paid during any fiscal year to an 

8 employee detailed to the Office as basic pay, 

9 awards, bonuses, and other compensation shall 

10 not exceed the annual rate payable at the end 

11 of such fiscal year for positions at level III of 

12 the Executive Schedule. 

13 ‘‘(d) CONGRESSIONAL ACCESS TO INFORMATION.— 

14 The location of the Office in the Executive Office of the 

15 President shall not be construed as affecting access by 

16 Congress, or any committee of the House of Representa17 tives or the Senate, to any— 

18 ‘‘(1) information, document, or study in the 

19 possession of, or conducted by or at the direction of 

20 the Director; or 

21 ‘‘(2) personnel of the Office. 

22 ‘‘(e) OTHER AUTHORITIES OF THE DIRECTOR.—In 

23 carrying out this chapter, the Director may— 

24 ‘‘(1) use for administrative purposes, on a reim25 bursable basis, the available services, equipment, 


sradovich on DSK3GMQ082PROD with BILLS
17 

HR 5925 RFS 

1 personnel, and facilities of Federal, State, and local 

2 agencies; 

3 ‘‘(2) procure the services of experts and con4 sultants in accordance with section 3109 of title 5 

5 relating to appointments in the Federal Service, at 

6 rates of compensation for individuals not to exceed 

7 the daily equivalent of the rate of pay payable under 

8 level IV of the Executive Schedule under section 

9 5311 of such title; and 

10 ‘‘(3) use the mails in the same manner as any 

11 other agency. 

12 ‘‘(f) GENERAL SERVICES ADMINISTRATION.—The 

13 Administrator of General Services shall provide to the Di14 rector, on a reimbursable basis, such administrative sup15 port services as the Director may request. 

16 ‘‘§ 1004. National drug control program budget 

17 ‘‘(a) BUDGET RECOMMENDATIONS.—Not later than 

18 July 1 of each year, the Director shall provide to the head 

19 of each National Drug Control Program Agency budget 

20 recommendations, including requests for specific initia21 tives that are consistent with the priorities of the Presi22 dent under the National Drug Control Strategy, which 

23 shall— 


sradovich on DSK3GMQ082PROD with BILLS
18 

HR 5925 RFS 

1 ‘‘(1) apply to the budget for the next fiscal year 

2 scheduled for formulation under chapter 11, and 

3 each of the 4 subsequent fiscal years; and 

4 ‘‘(2) address funding priorities developed in the 

5 National Drug Control Strategy. 

6 ‘‘(b) RESPONSIBILITIES OF NATIONAL DRUG CON7 TROL PROGRAM AGENCIES.— 

8 ‘‘(1) IN GENERAL.—For each fiscal year, the 

9 head of each National Drug Control Program Agen10 cy shall transmit to the Director a copy of the pro11 posed drug control budget request of such agency at 

12 the same time as that budget request is submitted 

13 to their superiors (and before submission to the Of14 fice of Management and Budget) in the preparation 

15 of the budget of the President submitted to Con16 gress under section 1105(a). 

17 ‘‘(2) SUBMISSION OF DRUG CONTROL BUDGET

18 REQUESTS.—The head of each National Drug Con19 trol Program Agency shall ensure timely develop20 ment and submission to the Director of each pro21 posed drug control budget request transmitted pur22 suant to this subsection, in such format as may be 

23 designated by the Director with the concurrence of 

24 the Director of the Office of Management and Budg25 et. 


sradovich on DSK3GMQ082PROD with BILLS
19 

HR 5925 RFS 

1 ‘‘(3) CONTENT OF DRUG CONTROL BUDGET RE2 QUESTS.—A drug control budget request submitted 

3 by the head of a National Drug Control Program 

4 Agency under this subsection shall include all re5 quests for funds for any drug control activity under6 taken by such agency, including demand reduction, 

7 supply reduction, and State, local, and Tribal af8 fairs, including any drug law enforcement activities. 

9 If an activity has both drug control and nondrug 

10 control purposes or applications, such agency shall 

11 estimate by a documented calculation the total funds 

12 requested for that activity that would be used for 

13 drug control, and shall set forth in its request the 

14 basis and method for making the estimate. 

15 ‘‘(c) REVIEW AND CERTIFICATION OF BUDGET RE16 QUESTS AND BUDGET SUBMISSIONS OF NATIONAL DRUG

17 CONTROL PROGRAM AGENCIES.— 

18 ‘‘(1) IN GENERAL.—The Director shall review 

19 each drug control budget request submitted to the 

20 Director under subsection (b). 

21 ‘‘(2) REVIEW OF BUDGET REQUESTS.— 

22 ‘‘(A) INADEQUATE REQUESTS.—If the Di23 rector concludes that a budget request sub24 mitted under subsection (b) is inadequate, in 

25 whole or in part, to implement the objectives of 


sradovich on DSK3GMQ082PROD with BILLS
20 

HR 5925 RFS 

1 the National Drug Control Strategy with re2 spect to the agency or program at issue for the 

3 year for which the request is submitted, the Di4 rector shall submit to the head of the applicable 

5 National Drug Control Program Agency a writ6 ten description identifying the funding levels 

7 and specific initiatives that would, in the deter8 mination of the Director, make the request ade9 quate to implement those objectives. 

10 ‘‘(B) ADEQUATE REQUESTS.—If the Direc11 tor concludes that a budget request submitted 

12 under subsection (b) is adequate to implement 

13 the objectives of the National Drug Control 

14 Strategy with respect to the agency or program 

15 at issue for the year for which the request is 

16 submitted, the Director shall submit to the 

17 head of the applicable National Drug Control 

18 Program Agency a written statement con19 firming the adequacy of the request. 

20 ‘‘(C) RECORD.—The Director shall main21 tain a record of each description submitted 

22 under subparagraph (A) and each statement 

23 submitted under subparagraph (B). 

24 ‘‘(3) SPECIFIC REQUESTS.—The Director shall 

25 not confirm the adequacy of any budget request that 


sradovich on DSK3GMQ082PROD with BILLS
21 

HR 5925 RFS 

1 requests a level of funding that will not enable 

2 achievement of the goals of the National Drug Con3 trol Strategy, including— 

4 ‘‘(A) requests funding for Federal law en5 forcement activities that do not adequately com6 pensate for transfers of drug enforcement re7 sources and personnel to law enforcement and 

8 investigation activities; 

9 ‘‘(B) requests funding for law enforcement 

10 activities on the borders of the United States 

11 that do not adequately direct resources to drug 

12 interdiction and enforcement; 

13 ‘‘(C) requests funding for substance use 

14 disorder treatment activities that do not provide 

15 adequate results and accountability measures; 

16 ‘‘(D) requests funding for substance use 

17 disorder treatment activities that do not ade18 quately support and enhance Federal substance 

19 use disorder programs and capacity; and 

20 ‘‘(E) requests funding for the operations 

21 and management of the Department of Home22 land Security that does not include a specific 

23 request for funds for the Office of Counter24 narcotics Enforcement to carry out its responVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00021 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
22 

HR 5925 RFS 

1 sibilities under section 878 of the Homeland Se2 curity Act of 2002 (6 U.S.C. 458). 

3 ‘‘(4) AGENCY RESPONSE.— 

4 ‘‘(A) IN GENERAL.—The head of a Na5 tional Drug Control Program Agency that re6 ceives a description under paragraph (2)(A) 

7 shall include the funding levels and initiatives 

8 described by the Director in the budget submis9 sion for that agency to the Office of Manage10 ment and Budget. 

11 ‘‘(B) IMPACT STATEMENT.—The head of a 

12 National Drug Control Program Agency that 

13 has altered its budget submission under this 

14 paragraph shall include as an appendix to the 

15 budget submission for that agency to the Office 

16 of Management and Budget an impact state17 ment that summarizes— 

18 ‘‘(i) the changes made to the budget 

19 under this paragraph; and 

20 ‘‘(ii) the impact of those changes on 

21 the ability of that agency to perform its 

22 other responsibilities, including any impact 

23 on specific missions or programs of the 

24 agency. 


sradovich on DSK3GMQ082PROD with BILLS
23 

HR 5925 RFS 

1 ‘‘(C) CONGRESSIONAL NOTIFICATION.— 

2 The head of a National Drug Control Program 

3 Agency shall submit a copy of any impact state4 ment under subparagraph (B) to the Senate, 

5 the House of Representatives, and the appro6 priate congressional committees, at the time the 

7 budget for that agency is submitted to Congress 

8 under section 1105(a). 

9 ‘‘(5) CERTIFICATION OF BUDGET SUBMIS10 SIONS.— 

11 ‘‘(A) IN GENERAL.—At the time the head 

12 of a National Drug Control Program Agency 

13 submits its budget request to the Office of 

14 Management and Budget, the head of the Na15 tional Drug Control Program Agency shall sub16 mit a copy of the budget request to the Direc17 tor. 

18 ‘‘(B) REVIEW AND CERTIFICATION OF

19 SUBMISSIONS.—The Director shall review each 

20 budget submission submitted under subpara21 graph (A) and submit to the appropriate con22 gressional committees one of the following: 

23 ‘‘(i) A written certification of the 

24 budget submission for the agency indi25 cating such request fully funds the NaVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00023 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
24 

HR 5925 RFS 

1 tional Drug Control Programs as necessary 

2 to achieve the goals of the National Drug 

3 Control Strategy, including a written state4 ment explaining the basis for the deter5 mination that the budget submission pro6 vides sufficient resources for the agency to 

7 achieve the goals of the Strategy. 

8 ‘‘(ii) A written certification of the 

9 budget submission for the agency indi10 cating such request partially funds the Na11 tional Drug Control Programs as necessary 

12 to achieve the goals of the Strategy, in13 cluding a written statement explaining the 

14 basis for the determination to certify the 

15 budget submission and identifying the level 

16 of funding sufficient to achieve the goals of 

17 the Strategy. 

18 ‘‘(iii) A written decertification of the 

19 budget submission for the agency indi20 cating the Director is unable to determine 

21 whether such budget submission for the 

22 agency fully funds or partially funds the 

23 National Drug Control Programs as nec24 essary to achieve the goals of the National 

25 Drug Control Strategy, including a written 


sradovich on DSK3GMQ082PROD with BILLS
25 

HR 5925 RFS 

1 statement identifying the additional infor2 mation necessary for the Director to make 

3 a determination on such budget submission 

4 and the level of funding sufficient to 

5 achieve the goals of the Strategy. 

6 ‘‘(iv) A written decertification of the 

7 budget submission for the agency indi8 cating that such budget is insufficient to 

9 fund the National Drug Control Programs 

10 as necessary to achieve the goals of the 

11 Strategy, including a written statement ex12 plaining the basis for the determination 

13 that the budget is insufficient and identi14 fying the level of funding sufficient to 

15 achieve the goals of the Strategy. 

16 ‘‘(d) NATIONAL DRUG CONTROL PROGRAM BUDGET

17 PROPOSAL.—For each fiscal year, following the trans18 mission of proposed drug control budget requests to the 

19 Director under subsection (b), the Director shall, in con20 sultation with the head of each National Drug Control 

21 Program Agency and the head of each major national or22 ganization that represents law enforcement officers, agen23 cies, or associations— 

24 ‘‘(1) develop a consolidated National Drug Con25 trol Program budget proposal designed to implement 


sradovich on DSK3GMQ082PROD with BILLS
26 

HR 5925 RFS 

1 the National Drug Control Strategy and to inform 

2 Congress and the public about the total amount pro3 posed to be spent on all supply reduction, demand 

4 reduction, State, local, and Tribal affairs, including 

5 any drug law enforcement, and other drug control 

6 activities by the Federal Government, which shall 

7 conform to the content requirements set forth in 

8 subsection (b)(3) and include— 

9 ‘‘(A) for each National Drug Control Pro10 gram Agency, a list of whether the funding level 

11 is full, partial, or insufficient to achieve the 

12 goals of the National Drug Control Strategy or 

13 whether the Director is unable to make such 

14 determination; 

15 ‘‘(B) a statement describing the extent to 

16 which any budget of a National Drug Control 

17 Program Agency with less than full funding 

18 hinders progress on achieving the goals of the 

19 National Drug Control Strategy; and 

20 ‘‘(C) alternative funding structures that 

21 could improve progress on achieving the goals 

22 of the National Drug Control Strategy; and 

23 ‘‘(2) submit the consolidated budget proposal to 

24 the President and Congress. 


sradovich on DSK3GMQ082PROD with BILLS
27 

HR 5925 RFS 

1 ‘‘(e) BUDGET ESTIMATE OR REQUEST SUBMISSION

2 TO CONGRESS.—Whenever the Director submits any 

3 budget estimate or request to the President or the Office 

4 of Management and Budget, the Director shall concur5 rently transmit to the appropriate congressional commit6 tees a detailed statement of the budgetary needs of the 

7 Office to execute its mission based on the good-faith as8 sessment of the Director. 

9 ‘‘(f) REPROGRAMMING AND TRANSFER REQUESTS.— 

10 ‘‘(1) IN GENERAL.—No National Drug Control 

11 Program Agency shall submit to Congress a re12 programming or transfer request with respect to any 

13 amount of appropriated funds in an amount exceed14 ing $1 million that is included in the National Drug 

15 Control Program budget unless the request has been 

16 approved by the Director. If the Director has not re17 sponded to a request for reprogramming subject to 

18 this paragraph within 30 days after receiving notice 

19 of the request having been made, the request shall 

20 be deemed approved by the Director under this para21 graph and forwarded to Congress. 

22 ‘‘(2) APPEAL.—The head of any National Drug 

23 Control Program Agency may appeal to the Presi24 dent any disapproval by the Director of a reVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00027 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
28 

HR 5925 RFS 

1 programming or transfer request under this sub2 section. 

3 ‘‘§ 1005. National drug control strategy 

4 ‘‘(a) IN GENERAL.— 

5 ‘‘(1) STATEMENT OF DRUG POLICY PRIOR6 ITIES.—The Director shall release a statement of 

7 drug control policy priorities in the calendar year of 

8 a Presidential inauguration following the inaugura9 tion but not later than April 1. 

10 ‘‘(2) NATIONAL DRUG CONTROL STRATEGY

11 SUBMITTED BY THE PRESIDENT.—Not later than 

12 the first Monday in February following the year in 

13 which the term of the President commences, the 

14 President shall submit to Congress a National Drug 

15 Control Strategy. 

16 ‘‘(b) DEVELOPMENT OF THE NATIONAL DRUG CON17 TROL STRATEGY.— 

18 ‘‘(1) PROMULGATION.—The Director shall pro19 mulgate the National Drug Control Strategy, which 

20 shall set forth a comprehensive plan to reduce illicit 

21 drug use and the consequences of such illicit drug 

22 use in the United States by limiting the availability 

23 of and reducing the demand for illegal drugs and 

24 promoting prevention, early intervention, treatment, 


sradovich on DSK3GMQ082PROD with BILLS
29 

HR 5925 RFS 

1 and recovery support for individuals with substance 

2 use disorders. 

3 ‘‘(2) STATE AND LOCAL COMMITMENT.—The 

4 Director shall seek the support and commitment of 

5 State, local, and Tribal officials in the formulation 

6 and implementation of the National Drug Control 

7 Strategy. 

8 ‘‘(3) STRATEGY BASED ON EVIDENCE.—The Di9 rector shall ensure the National Drug Control Strat10 egy is based on the best available medical and sci11 entific evidence regarding the policies that are most 

12 effective in reducing the demand for and supply of 

13 illegal drugs. 

14 ‘‘(4) PROCESS FOR DEVELOPMENT AND SUB15 MISSION OF NATIONAL DRUG CONTROL STRATEGY.— 

16 In developing and effectively implementing the Na17 tional Drug Control Strategy, the Director— 

18 ‘‘(A) shall consult with— 

19 ‘‘(i) the heads of the National Drug 

20 Control Program Agencies; 

21 ‘‘(ii) each Coordinator established 

22 under this chapter; 

23 ‘‘(iii) the Interdiction Committee, the 

24 Treatment Committee, and the Emerging 

25 Threats Task Force; 


sradovich on DSK3GMQ082PROD with BILLS
30 

HR 5925 RFS 

1 ‘‘(iv) the appropriate congressional 

2 committees and any other committee of ju3 risdiction; 

4 ‘‘(v) State, local, and Tribal officials; 

5 ‘‘(vi) private citizens and organiza6 tions, including community and faith-based 

7 organizations, with experience and exper8 tise in demand reduction; 

9 ‘‘(vii) private citizens and organiza10 tions with experience and expertise in sup11 ply reduction; and 

12 ‘‘(viii) appropriate representatives of 

13 foreign governments; and 

14 ‘‘(B) in satisfying the requirements of sub15 paragraph (A), shall ensure, to the maximum 

16 extent possible, that State, local, and Tribal of17 ficials and relevant private organizations com18 mit to support and take steps to achieve the 

19 goals and objectives of the National Drug Con20 trol Strategy. 

21 ‘‘(c) CONTENTS OF THE NATIONAL DRUG CONTROL

22 STRATEGY.— 

23 ‘‘(1) IN GENERAL.—The National Drug Control 

24 Strategy submitted under subsection (a)(2) shall in25 clude the following: 


sradovich on DSK3GMQ082PROD with BILLS
31 

HR 5925 RFS 

1 ‘‘(A) A description of the current preva2 lence of illicit drug use in the United States, in3 cluding both the availability of illicit drugs and 

4 the prevalence of substance use disorders, which 

5 shall include the following: 

6 ‘‘(i) Such description for the previous 

7 3 years for any drug identified as an 

8 emerging threat under section 1009 and 

9 any other illicit drug identified by the Di10 rector as having a significant impact on 

11 the prevalence of illicit drug use. 

12 ‘‘(ii) A summary of the data and 

13 trends presented in the Drug Control Data 

14 Dashboard required under section 1013. 

15 ‘‘(B) A mission statement detailing the 

16 major functions of the National Drug Control 

17 Program. 

18 ‘‘(C) A list of comprehensive, research19 based, long-range, quantifiable goals for reduc20 ing illicit drug use, including— 

21 ‘‘(i) the percentage of the total flow of 

22 illicit drugs to be interdicted during the 

23 time period covered by the Strategy; and 

24 ‘‘(ii) the number of individuals to re25 ceive substance use disorder treatment. 


sradovich on DSK3GMQ082PROD with BILLS
32 

HR 5925 RFS 

1 ‘‘(D) A description of how each goal estab2 lished under subparagraph (C) will be achieved, 

3 including for each goal— 

4 ‘‘(i) a list of each relevant National 

5 Drug Control Program Agency and each 

6 such agency’s related programs, activities, 

7 and available assets and the role of each 

8 such program, activity, and asset in achiev9 ing such goal; 

10 ‘‘(ii) a list of relevant stakeholders 

11 and each such stakeholder’s role in achiev12 ing such goal; 

13 ‘‘(iii) an estimate of Federal funding 

14 and other resources needed to achieve such 

15 goal; 

16 ‘‘(iv) a list of each existing or new co17 ordinating mechanism needed to achieve 

18 such goal; and 

19 ‘‘(v) a description of the Office’s role 

20 in facilitating the achievement of such 

21 goal. 

22 ‘‘(E) For each year covered by the Strat23 egy, a performance evaluation plan for each 

24 goal established under subparagraph (C) for 


sradovich on DSK3GMQ082PROD with BILLS
33 

HR 5925 RFS 

1 each National Drug Control Program Agency, 

2 including— 

3 ‘‘(i) specific performance measures for 

4 each National Drug Control Program 

5 Agency and each such agency’s related 

6 programs and activities; 

7 ‘‘(ii) annual and, to the extent prac8 ticable, quarterly objectives and targets for 

9 each performance measure; and 

10 ‘‘(iii) an estimate of Federal funding 

11 and other resources needed to achieve each 

12 performance objective and target. 

13 ‘‘(F) A list identifying existing data 

14 sources or a description of data collection need15 ed to evaluate performance, including a descrip16 tion of how the Director will obtain such data. 

17 ‘‘(G) A list of any anticipated challenges to 

18 achieving the National Drug Control Strategy 

19 goals and planned actions to address such chal20 lenges. 

21 ‘‘(H) A description of how each goal estab22 lished under subparagraph (C) was determined, 

23 including— 


sradovich on DSK3GMQ082PROD with BILLS
34 

HR 5925 RFS 

1 ‘‘(i) a description of each required 

2 consultation and a description of how such 

3 consultation was incorporated; 

4 ‘‘(ii) data, research, or other informa5 tion used to inform the determination to 

6 establish the goal; and 

7 ‘‘(iii) for any goal established under 

8 subparagraph (C)(i), a statement of wheth9 er the goal will be adequate to disrupt 

10 drug trafficking organizations that supply 

11 the majority of foreign-sourced illicit drugs 

12 trafficked into the United States. 

13 ‘‘(I) A 5-year projection for program and 

14 budget priorities. 

15 ‘‘(J) A review of international, State, local, 

16 and private sector drug control activities to en17 sure that the United States pursues coordinated 

18 and effective drug control at all levels of gov19 ernment. 

20 ‘‘(K) Such statistical data and information 

21 as the Director considers appropriate to dem22 onstrate and assess trends relating to illicit 

23 drug use, the effects and consequences of illicit 

24 drug use (including the effects on children), 

25 supply reduction, demand reduction, drug-reVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00034 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
35 

HR 5925 RFS 

1 lated law enforcement, and the implementation 

2 of the National Drug Control Strategy. 

3 ‘‘(2) ADDITIONAL STRATEGIES.— 

4 ‘‘(A) IN GENERAL.—The Director shall in5 clude in the National Drug Control Strategy 

6 the additional strategies described under this 

7 paragraph and shall comply with the following: 

8 ‘‘(i) Provide a copy of the additional 

9 strategies to the appropriate congressional 

10 committees and to the Committee on 

11 Armed Services and the Committee on 

12 Homeland Security of the House of Rep13 resentatives, and the Committee on Home14 land Security and Governmental Affairs 

15 and the Committee on Armed Services of 

16 the Senate. 

17 ‘‘(ii) Issue the additional strategies in 

18 consultation with the head of each relevant 

19 National Drug Control Program Agency, 

20 any relevant official of a State, local, or 

21 Tribal government, and the government of 

22 other relevant countries. 

23 ‘‘(iii) Not change any existing agency 

24 authority or construe any strategy de25 scribed under this paragraph to amend or 


sradovich on DSK3GMQ082PROD with BILLS
36 

HR 5925 RFS 

1 modify any law governing interagency rela2 tionship but may include recommendations 

3 about changes to such authority or law. 

4 ‘‘(iv) Present separately from the rest 

5 of any strategy described under this para6 graph any information classified under cri7 teria established by an Executive order, or 

8 whose public disclosure, as determined by 

9 the Director or the head of any relevant 

10 National Drug Control Program Agency, 

11 would be detrimental to the law enforce12 ment or national security activities of any 

13 Federal, State, local, or Tribal agency. 

14 ‘‘(B) REQUIREMENT FOR SOUTHWEST

15 BORDER COUNTERNARCOTICS.— 

16 ‘‘(i) PURPOSES.—The Southwest Bor17 der Counternarcotics Strategy shall— 

18 ‘‘(I) set forth the Government’s 

19 strategy for preventing the illegal traf20 ficking of drugs across the inter21 national border between the United 

22 States and Mexico, including through 

23 ports of entry and between ports of 

24 entry on that border; 


sradovich on DSK3GMQ082PROD with BILLS
37 

HR 5925 RFS 

1 ‘‘(II) state the specific roles and 

2 responsibilities of the relevant Na3 tional Drug Control Program Agen4 cies for implementing that strategy; 

5 and 

6 ‘‘(III) identify the specific re7 sources required to enable the relevant 

8 National Drug Control Program 

9 Agencies to implement that strategy. 

10 ‘‘(ii) SPECIFIC CONTENT RELATED TO

11 DRUG TUNNELS BETWEEN THE UNITED

12 STATES AND MEXICO.—The Southwest 

13 Border Counternarcotics Strategy shall in14 clude— 

15 ‘‘(I) a strategy to end the con16 struction and use of tunnels and sub17 terranean passages that cross the 

18 international border between the 

19 United States and Mexico for the pur20 pose of illegal trafficking of drugs 

21 across such border; and 

22 ‘‘(II) recommendations for crimi23 nal penalties for persons who con24 struct or use such a tunnel or sub25 terranean passage for such a purpose. 


sradovich on DSK3GMQ082PROD with BILLS
38 

HR 5925 RFS 

1 ‘‘(C) REQUIREMENT FOR NORTHERN BOR2 DER COUNTERNARCOTICS STRATEGY.— 

3 ‘‘(i) PURPOSES.—The Northern Bor4 der Counternarcotics Strategy shall— 

5 ‘‘(I) set forth the strategy of the 

6 Federal Government for preventing 

7 the illegal trafficking of drugs across 

8 the international border between the 

9 United States and Canada, including 

10 through ports of entry and between 

11 ports of entry on the border; 

12 ‘‘(II) state the specific roles and 

13 responsibilities of each relevant Na14 tional Drug Control Program Agency 

15 for implementing the strategy; 

16 ‘‘(III) identify the specific re17 sources required to enable the relevant 

18 National Drug Control Program 

19 Agencies to implement the strategy; 

20 ‘‘(IV) be designed to promote, 

21 and not hinder, legitimate trade and 

22 travel; and 

23 ‘‘(V) reflect the unique nature of 

24 small communities along the inter25 national border between the United 


sradovich on DSK3GMQ082PROD with BILLS
39 

HR 5925 RFS 

1 States and Canada, ongoing coopera2 tion and coordination with Canadian 

3 law, enforcement authorities, and 

4 variations in the volumes of vehicles 

5 and pedestrians crossing through 

6 ports of entry along the international 

7 border between the United States and 

8 Canada. 

9 ‘‘(ii) SPECIFIC CONTENT RELATED TO

10 CROSS-BORDER INDIAN RESERVATIONS.— 

11 The Northern Border Counternarcotics 

12 Strategy shall include— 

13 ‘‘(I) a strategy to end the illegal 

14 trafficking of drugs to or through In15 dian reservations on or near the inter16 national border between the United 

17 States and Canada; and 

18 ‘‘(II) recommendations for addi19 tional assistance, if any, needed by 

20 Tribal law enforcement agencies relat21 ing to the strategy, including an eval22 uation of Federal technical and finan23 cial assistance, infrastructure capacity 

24 building, and interoperability defi25 ciencies. 


sradovich on DSK3GMQ082PROD with BILLS
40 

HR 5925 RFS 

1 ‘‘(3) CLASSIFIED INFORMATION.—Any contents 

2 of the National Drug Control Strategy that involve 

3 information properly classified under criteria estab4 lished by an Executive order shall be presented to 

5 Congress separately from the rest of the National 

6 Drug Control Strategy. 

7 ‘‘(4) SELECTION OF DATA AND INFORMA8 TION.—In selecting data and information for inclu9 sion in the Strategy, the Director shall ensure— 

10 ‘‘(A) the inclusion of data and information 

11 that will permit analysis of current trends 

12 against previously compiled data and informa13 tion where the Director believes such analysis 

14 enhances long-term assessment of the National 

15 Drug Control Strategy; and 

16 ‘‘(B) the inclusion of data and information 

17 to permit a standardized and uniform assess18 ment of the effectiveness of drug treatment pro19 grams in the United States. 

20 ‘‘(d) ANNUAL PERFORMANCE SUPPLEMENT.—Not 

21 later than the first Monday in February of each year fol22 lowing the year in which the National Drug Control Strat23 egy is submitted pursuant to subsection (a)(2), the Direc24 tor shall submit to the appropriate congressional commit25 tees a supplement to the Strategy that shall include— 


sradovich on DSK3GMQ082PROD with BILLS
41 

HR 5925 RFS 

1 ‘‘(1) annual and, to the extent practicable, 

2 quarterly quantifiable and measurable objectives and 

3 specific targets to accomplish long-term quantifiable 

4 goals specified in the Strategy; and 

5 ‘‘(2) for each year covered by the Strategy, a 

6 performance evaluation plan for each goal listed in 

7 the Strategy for each National Drug Control Pro8 gram Agency, including— 

9 ‘‘(A) specific performance measures for 

10 each National Drug Control Program Agency 

11 and each such agency’s related programs and 

12 activities; 

13 ‘‘(B) annual and, to the extent practicable, 

14 quarterly objectives and targets for each per15 formance measure; and 

16 ‘‘(C) an estimate of Federal funding and 

17 other resources needed to achieve each perform18 ance objective and target. 

19 ‘‘(e) SUBMISSION OF REVISED STRATEGY.— 

20 ‘‘(1) IN GENERAL.—The President may submit 

21 to Congress a revised National Drug Control Strat22 egy that meets the requirements of this section— 

23 ‘‘(A) at any time, upon a determination of 

24 the President, in consultation with the Director, 


sradovich on DSK3GMQ082PROD with BILLS
42 

HR 5925 RFS 

1 that the National Drug Control Strategy in ef2 fect is not sufficiently effective; or 

3 ‘‘(B) if a new President or Director takes 

4 office. 

5 ‘‘(2) NO SUBMISSION.—In each year the Presi6 dent does not submit a National Drug Control 

7 Strategy or a revised National Drug Control Strat8 egy, the Director shall evaluate the efficacy and ap9 propriateness of the goals of the National Drug Con10 trol Strategy and include a statement affirming the 

11 adequacy of the goals in the performance supple12 ment under subsection (d). 

13 ‘‘(f) FAILURE OF PRESIDENT TO SUBMIT NATIONAL

14 DRUG CONTROL STRATEGY.—If the President does not 

15 submit a National Drug Control Strategy to Congress in 

16 accordance with subsection (a)(2), not later than 5 days 

17 after the first Monday in February following the year in 

18 which the term of the President commences, the President 

19 shall send a notification to the appropriate congressional 

20 committees— 

21 ‘‘(1) explaining why the Strategy was not sub22 mitted; and 

23 ‘‘(2) specifying the date by which the Strategy 

24 will be submitted. 


sradovich on DSK3GMQ082PROD with BILLS
43 

HR 5925 RFS 

1 ‘‘§ 1006. Development of an annual national drug con2 trol assessment 

3 ‘‘(a) TIMING.—Not later than the first Monday in 

4 February of each year, the Director shall submit to the 

5 President, Congress, and the appropriate congressional 

6 committees, a report assessing the progress of each Na7 tional Drug Control Program Agency toward achieving 

8 each goal, objective, and target contained in the National 

9 Drug Control Strategy applicable to the prior fiscal year. 

10 ‘‘(b) PROCESS FOR DEVELOPMENT OF THE ANNUAL

11 ASSESSMENT.—Not later than November 1 of each year, 

12 the head of each National Drug Control Program Agency 

13 shall submit, in accordance with guidance issued by the 

14 Director, to the Director an evaluation of progress by the 

15 agency with respect to the National Drug Control Strategy 

16 goals using the performance measures for the agency de17 veloped under this chapter, including progress with respect 

18 to— 

19 ‘‘(1) success in achieving the goals of the Na20 tional Drug Control Strategy; 

21 ‘‘(2) success in reducing domestic and foreign 

22 sources of illegal drugs; 

23 ‘‘(3) success in expanding access to and in24 creasing the effectiveness of substance use disorder 

25 treatment; 


sradovich on DSK3GMQ082PROD with BILLS
44 

HR 5925 RFS 

1 ‘‘(4) success in protecting the borders of the 

2 United States (and in particular the Southwestern 

3 border of the United States) from penetration by il4 legal narcotics; 

5 ‘‘(5) success in reducing crime associated with 

6 drug use in the United States; 

7 ‘‘(6) success in reducing the negative health 

8 and social consequences of drug use in the United 

9 States; and 

10 ‘‘(7) implementation of substance use disorder 

11 treatment and prevention programs in the United 

12 States and improvements in the adequacy and effec13 tiveness of such programs. 

14 ‘‘(c) CONTENTS OF THE ANNUAL ASSESSMENT.— 

15 The Director shall include in the annual assessment re16 quired under subsection (a)— 

17 ‘‘(1) a summary of each evaluation received by 

18 the Director under subsection (b); 

19 ‘‘(2) a summary of the progress of each Na20 tional Drug Control Program Agency toward the 

21 National Drug Control Strategy goals of the agency 

22 using the performance measures for the agency de23 veloped under this chapter; 

24 ‘‘(3) an assessment of the effectiveness of each 

25 National Drug Control Program Agency and proVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00044 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
45 

HR 5925 RFS 

1 gram in achieving the National Drug Control Strat2 egy for the previous year, including a specific evalua3 tion of whether the applicable goals, measures, ob4 jectives, and targets for the previous year were met; 

5 ‘‘(4) for each National Drug Control Program 

6 Agency that administers grant programs, an evalua7 tion of the effectiveness of each grant program, in8 cluding an accounting of the funds disbursed by the 

9 program in the prior year and a summary of how 

10 those funds were used by the grantees and sub11 grantees during that period; 

12 ‘‘(5) a detailed accounting of the amount of 

13 funds obligated by each National Drug Control Pro14 gram Agency in carrying out the responsibilities of 

15 that agency under the Strategy; 

16 ‘‘(6) an assessment of the effectiveness of any 

17 Emerging Threat Response Plan in effect for the 

18 previous year, including a specific evaluation of 

19 whether the objectives and targets were met and rea20 sons for the success or failure of the previous year’s 

21 plan; 

22 ‘‘(7) a detailed accounting of the amount of 

23 funds obligated during the previous fiscal year for 

24 carrying out the campaign under section 1009(d), 

25 including each recipient of funds, the purpose of 


sradovich on DSK3GMQ082PROD with BILLS
46 

HR 5925 RFS 

1 each expenditure, the amount of each expenditure, 

2 any available outcome information, and any other in3 formation necessary to provide a complete account4 ing of the funds expended; and 

5 ‘‘(8) the assessments required under this sub6 section shall be based on the Performance Measure7 ment System describe in subsection (d). 

8 ‘‘(d) PERFORMANCE MEASUREMENT SYSTEM.—The 

9 Director shall include in the annual assessment required 

10 under subsection (a) a national drug control performance 

11 measurement system, that— 

12 ‘‘(1) develops annual, 2-year, and 5-year per13 formance measures, objectives, and targets for each 

14 National Drug Control Strategy goal and objective 

15 established for reducing drug use, availability, and 

16 the consequences of drug use; 

17 ‘‘(2) describes the sources of information and 

18 data that will be used for each performance measure 

19 incorporated into the performance measurement sys20 tem; 

21 ‘‘(3) identifies major programs and activities of 

22 the National Drug Control Program Agencies that 

23 support the goals and annual objectives of the Na24 tional Drug Control Strategy; 


sradovich on DSK3GMQ082PROD with BILLS
47 

HR 5925 RFS 

1 ‘‘(4) evaluates the contribution of demand re2 duction and supply reduction activities implemented 

3 by each National Drug Control Program Agency in 

4 support of the National Drug Control Strategy; 

5 ‘‘(5) monitors consistency between the drug-re6 lated goals, measures, targets, and objectives of the 

7 National Drug Control Program Agencies and en8 sures that each agency’s goals and budgets support, 

9 and are fully consistent with, the National Drug 

10 Control Strategy; and 

11 ‘‘(6) coordinates the development and imple12 mentation of national drug control data collection 

13 and reporting systems to support policy formulation 

14 and performance measurement, including an assess15 ment of— 

16 ‘‘(A) the quality of current drug use meas17 urement instruments and techniques to measure 

18 supply reduction and demand reduction activi19 ties; 

20 ‘‘(B) the adequacy of the coverage of exist21 ing national drug use measurement instruments 

22 and techniques to measure the illicit drug user 

23 population and groups that are at risk for illicit 

24 drug use; 


sradovich on DSK3GMQ082PROD with BILLS
48 

HR 5925 RFS 

1 ‘‘(C) the adequacy of the coverage of exist2 ing national treatment outcome monitoring sys3 tems to measure the effectiveness of substance 

4 use disorder treatment in reducing illicit drug 

5 use and criminal behavior during and after the 

6 completion of substance use disorder treatment; 

7 and 

8 ‘‘(D) the actions the Director shall take to 

9 correct any deficiencies and limitations identi10 fied pursuant to subparagraphs (A), (B), and 

11 (C). 

12 ‘‘(e) MODIFICATIONS.—A description of any modi13 fications made during the preceding year to the national 

14 drug performance measurement system described in sub15 section (d) shall be included in each report submitted 

16 under subsection (a). 

17 ‘‘(f) ANNUAL REPORT ON CONSULTATION.—The Di18 rector shall include in the annual assessment required 

19 under subsection (a)— 

20 ‘‘(1) a detailed description of how the Office 

21 has consulted with and assisted State, local, and 

22 Tribal governments with respect to the formulation 

23 and implementation of the National Drug Control 

24 Strategy and other relevant issues; and 


sradovich on DSK3GMQ082PROD with BILLS
49 

HR 5925 RFS 

1 ‘‘(2) a general review of the status of, and 

2 trends in, demand reduction activities by private sec3 tor entities and community-based organizations, in4 cluding faith-based organizations, to determine their 

5 effectiveness and the extent of cooperation, coordina6 tion, and mutual support between such entities and 

7 organizations and Federal, State, local, and Tribal 

8 government agencies. 

9 ‘‘(g) PERFORMANCE-BUDGET COORDINATOR.— 

10 ‘‘(1) DESIGNATION.—The Director shall des11 ignate or appoint a United States Performance12 Budget Coordinator to— 

13 ‘‘(A) ensure the Director has sufficient in14 formation necessary to analyze the performance 

15 of each National Drug Control Program Agen16 cy, the impact Federal funding has had on the 

17 goals in the Strategy, and the likely contribu18 tions to the goals of the Strategy based on 

19 funding levels of each National Drug Control 

20 Program Agency, to make an independent as21 sessment of the budget request of each agency 

22 under section 1004; 

23 ‘‘(B) advise the Director on agency budg24 ets, performance measures and targets, and ad25 ditional data and research needed to make inVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00049 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
50 

HR 5925 RFS 

1 formed policy decisions under sections 1004 and 

2 1005; and 

3 ‘‘(C) other duties as may be determined by 

4 the Director with respect to measuring or as5 sessing performance or agency budgets. 

6 ‘‘(2) DETERMINATION OF POSITION.—The Di7 rector shall determine whether the coordinator posi8 tion is a noncareer appointee in the Senior Executive 

9 Service or a career appointee at the GS–15 level (or 

10 equivalent) or above. 

11 ‘‘§ 1007. Monitoring and evaluation of national drug 

12 control program 

13 ‘‘(a) IN GENERAL.—The Director shall monitor im14 plementation of the National Drug Control Program and 

15 the activities of the National Drug Control Program Agen16 cies in carrying out the goals and objectives of the Na17 tional Drug Control Strategy including— 

18 ‘‘(1) conducting program and performance au19 dits and evaluations; and 

20 ‘‘(2) requesting assistance from the Inspector 

21 General of the relevant agency in such audits and 

22 evaluations. 

23 ‘‘(b) ACCOUNTING OF FUNDS EXPENDED.—(1) Not 

24 later than February 1 of each year, in accordance with 

25 guidance issued by the Director, the head of each National 


sradovich on DSK3GMQ082PROD with BILLS
51 

HR 5925 RFS 

1 Drug Control Program Agency shall submit to the Direc2 tor a detailed accounting of all funds expended by the 

3 agency for National Drug Control Program activities dur4 ing the previous fiscal year and shall ensure such detailed 

5 accounting is authenticated for the previous fiscal year by 

6 the Inspector General for such agency prior to the submis7 sion to the Director as frequently as determined by the 

8 Inspector General but not less frequently that every 3 

9 years. 

10 ‘‘(2) The Director shall submit to Congress not later 

11 than April 1 of each year the information submitted to 

12 the Director under paragraph (1). 

13 ‘‘(c) NOTIFICATION.—The Director shall notify any 

14 National Drug Control Program Agency if its activities 

15 are not in compliance with the responsibilities of the agen16 cy under the National Drug Control Strategy, transmit 

17 a copy of each such notification to the President and the 

18 appropriate congressional committees, and maintain a 

19 copy of each such notification. 

20 ‘‘(d) RECOMMENDATIONS.—The Director shall make 

21 such recommendations to the President and the appro22 priate congressional committees as the Director deter23 mines are appropriate regarding changes in the organiza24 tion, management, and budgets of the National Drug Con25 trol Program Agencies, and changes in the allocation of 


sradovich on DSK3GMQ082PROD with BILLS
52 

HR 5925 RFS 

1 personnel to and within those agencies, to implement the 

2 policies, goals, objectives, and priorities established under 

3 section 1002(c)(1) and the National Drug Control Strat4 egy. 

5 ‘‘(e) AUTHORIZATION, DEVELOPMENT, AND IMPLE6 MENTATION OF A COORDINATED TRACKING SYSTEM.— 

7 ‘‘(1) ESTABLISHMENT.—The Director shall es8 tablish a coordinated tracking system of federally9 funded initiatives and grant programs which shall— 

10 ‘‘(A) be the central repository of all drug 

11 control grants; 

12 ‘‘(B) identify duplication, overlap, or gaps 

13 in funding to provide increased accountability of 

14 federally-funded grants for substance use dis15 order treatment, prevention, and enforcement; 

16 ‘‘(C) identify impediments that applicants 

17 currently have in the grant application process 

18 with applicable agencies; and 

19 ‘‘(D) be developed and maintained by the 

20 Office with the support of designated National 

21 Drug Control Program Agencies and any other 

22 agency determined by the Director. 

23 ‘‘(2) PERFORMANCE METRICS.—The Director 

24 shall identify metrics and achievable goals for grant 

25 recipients in furtherance of the Strategy. Such 


sradovich on DSK3GMQ082PROD with BILLS
53 

HR 5925 RFS 

1 metrics shall be used to measure how effective each 

2 federally funded initiative is in achieving the objec3 tives of the Strategy and to enable comparisons of 

4 federally funded initiatives to identify those that are 

5 the most cost effective. 

6 ‘‘(3) GRANT APPLICATION STANDARDIZA7 TION.—To reduce the administrative burden on 

8 grant applicants and improve oversight of Federal 

9 funds, the Director, in consultation with the head of 

10 each National Drug Control Program Agency, shall 

11 develop a plan for coordinating and standardizing 

12 drug control grant application processes and develop 

13 a joint application to be used by all National Drug 

14 Control Program Agencies. 

15 ‘‘(4) CENTRAL PORTAL.—The Director shall 

16 maintain on the public, electronic portal of the Of17 fice a list all drug control grant programs available 

18 in a central location. The head of each National 

19 Drug Control Program Agency shall provide a com20 plete list of all drug control program grant programs 

21 to the Director and annually update such list. 

22 ‘‘(5) REPORT TO CONGRESS.—The Director 

23 shall include in the assessment submitted to Con24 gress under section 1006 an assessment on progress 

25 under this section. 


sradovich on DSK3GMQ082PROD with BILLS
54 

HR 5925 RFS 

1 ‘‘§ 1008. Coordination and oversight of the national 

2 drug control program 

3 ‘‘(a) IN GENERAL.—The Director shall coordinate 

4 and oversee the implementation by the National Drug 

5 Control Program Agencies of the policies, goals, objectives, 

6 and priorities established under section 1002(c)(1) and 

7 the fulfillment of the responsibilities of such agencies 

8 under the National Drug Control Strategy and make rec9 ommendations to National Drug Control Program Agency 

10 heads with respect to implementation of National Drug 

11 Control Programs. 

12 ‘‘(b) DETAILING EMPLOYEES TO OTHER AGEN13 CIES.— 

14 ‘‘(1) REQUEST.—The Director may request the 

15 head of an agency or program of the Federal Gov16 ernment to place agency personnel who are engaged 

17 in drug control activities on temporary detail to an18 other agency in order to implement the National 

19 Drug Control Strategy. 

20 ‘‘(2) AGENCY COMPLIANCE.—The head of the 

21 agency shall comply with any request made under 

22 paragraph (1). 

23 ‘‘(3) MAXIMUM NUMBER OF DETAILEES.—The 

24 maximum number of personnel who may be detailed 

25 to another agency (including the Office) under this 

26 subsection during any fiscal year is— 


sradovich on DSK3GMQ082PROD with BILLS
55 

HR 5925 RFS 

1 ‘‘(A) for the Department of Defense, 50; 

2 and 

3 ‘‘(B) for any other agency, 10. 

4 ‘‘(c) DIRECTING FEDERAL FUNDING.—The Director 

5 may transfer funds made available to a National Drug 

6 Control Program Agency for National Drug Control Strat7 egy programs and activities to another account within 

8 such agency or to another National Drug Control Program 

9 Agency for National Drug Control Strategy programs and 

10 activities, except that— 

11 ‘‘(1) the authority under this subsection may be 

12 limited in an annual appropriations Act or other 

13 provision of Federal law; 

14 ‘‘(2) the Director may exercise the authority 

15 under this subsection only with the concurrence of 

16 the head of each affected agency; 

17 ‘‘(3) in the case of an interagency transfer, the 

18 total amount of transfers under this subsection may 

19 not exceed 3 percent of the total amount of funds 

20 made available for National Drug Control Strategy 

21 programs and activities to the agency from which 

22 those funds are to be transferred; 

23 ‘‘(4) funds transferred to an agency under this 

24 subsection may only be used to increase the funding 

25 for programs or activities authorized by law; 


sradovich on DSK3GMQ082PROD with BILLS
56 

HR 5925 RFS 

1 ‘‘(5) the Director shall— 

2 ‘‘(A) submit to the appropriate congres3 sional committees and any other applicable 

4 committee of jurisdiction, a reprogramming or 

5 transfer request in advance of any transfer 

6 under this subsection in accordance with the 

7 regulations of each affected agency; and 

8 ‘‘(B) annually submit to the appropriate 

9 congressional committees a report describing 

10 the effect of all transfers of funds made pursu11 ant to this subsection or section 1004(f) during 

12 the 12-month period preceding the date on 

13 which the report is submitted; and 

14 ‘‘(6) funds may only be used for— 

15 ‘‘(A) expansion of demand reduction activi16 ties; 

17 ‘‘(B) interdiction of illicit drugs on the 

18 high seas, in United States territorial waters, 

19 and at United States ports of entry by officers 

20 and employees of National Drug Control Pro21 gram Agencies and domestic and foreign law 

22 enforcement officers; 

23 ‘‘(C) accurate assessment and monitoring 

24 of international drug production and interdic25 tion programs and policies; 


sradovich on DSK3GMQ082PROD with BILLS
57 

HR 5925 RFS 

1 ‘‘(D) activities to facilitate and enhance 

2 the sharing of domestic and foreign intelligence 

3 information among National Drug Control Pro4 gram Agencies related to the production and 

5 trafficking of drugs in the United States and 

6 foreign countries; 

7 ‘‘(E) activities to prevent the diversion of 

8 prescription drugs for illicit use; and 

9 ‘‘(F) research related to any of these ac10 tivities. 

11 ‘‘(d) DIRECTING FEDERAL FUNDING TO RESPOND

12 TO EMERGING THREATS.— 

13 ‘‘(1) IN GENERAL.—The Director may transfer 

14 funds made available to a National Drug Control 

15 Program Agency for National Drug Control Strategy 

16 programs and activities to another account within 

17 such agency or to another National Drug Control 

18 Program Agency for National Drug Control Strategy 

19 programs and activities to implement the provisions 

20 of a plan developed under section 1009, except 

21 that— 

22 ‘‘(A) the authority under this subsection 

23 may be limited in an annual appropriations Act 

24 or other provision of Federal law; 


sradovich on DSK3GMQ082PROD with BILLS
58 

HR 5925 RFS 

1 ‘‘(B) the Director may exercise the author2 ity under this subsection only with the concur3 rence of the head of each affected agency; 

4 ‘‘(C) in the case of an interagency transfer, 

5 the total amount of transfers under this sub6 section may not exceed 10 percent of the total 

7 amount of funds made available for National 

8 Drug Control Strategy programs and activities 

9 to the agency from which those funds are to be 

10 transferred; 

11 ‘‘(D) funds transferred to an agency under 

12 this subsection may only be used to increase the 

13 funding for programs or activities authorized by 

14 law; 

15 ‘‘(E) no transfer of funds under this sub16 section may result in a reduction in total Fed17 eral expenditures for substance use disorder 

18 treatment; 

19 ‘‘(F) the Director shall— 

20 ‘‘(i) submit to the appropriate con21 gressional committees and any other appli22 cable committee of jurisdiction, a re23 programming or transfer request in ad24 vance of any transfer under this subsection 


sradovich on DSK3GMQ082PROD with BILLS
59 

HR 5925 RFS 

1 in accordance with the regulations of each 

2 affected agency; and 

3 ‘‘(ii) annually submit to the appro4 priate congressional committees a report 

5 describing the effect of all transfers of 

6 funds made pursuant to this subsection or 

7 section 1004(f) during the 12-month pe8 riod preceding the date on which the report 

9 is submitted; and 

10 ‘‘(G) funds may only be used for— 

11 ‘‘(i) expansion of demand reduction 

12 activities; 

13 ‘‘(ii) interdiction of illicit drugs on the 

14 high seas, in United States territorial 

15 waters, and at United States ports of entry 

16 by officers and employees of National 

17 Drug Control Program Agencies and do18 mestic and foreign law enforcement offi19 cers; 

20 ‘‘(iii) accurate assessment and moni21 toring of international drug production and 

22 interdiction programs and policies; 

23 ‘‘(iv) activities to facilitate and en24 hance the sharing of domestic and foreign 

25 intelligence information among National 


sradovich on DSK3GMQ082PROD with BILLS
60 

HR 5925 RFS 

1 Drug Control Program Agencies related to 

2 the production and trafficking of drugs in 

3 the United States and foreign countries; 

4 ‘‘(v) activities to prevent the diversion 

5 of prescription drugs for illicit use; and 

6 ‘‘(vi) research related to any of these 

7 activities. 

8 ‘‘(2) INADEQUACY OF TRANSFER.—In the event 

9 the authority under this subsection is inadequate to 

10 implement the provisions of a plan developed under 

11 section 1009, the Director shall submit a request for 

12 funding to the appropriate congressional committees 

13 within 30 days after the date on which the Director 

14 determines there is a need for additional funding. 

15 ‘‘(e) FUND CONTROL NOTICES.— 

16 ‘‘(1) IN GENERAL.—The Director may issue to 

17 the head of a National Drug Control Program Agen18 cy a fund control notice to ensure compliance with 

19 the National Drug Control Program Strategy. A 

20 fund control notice may direct that all or part of an 

21 amount appropriated to the National Drug Control 

22 Program Agency account be obligated by— 

23 ‘‘(A) months, fiscal year quarters, or other 

24 time periods; and 


sradovich on DSK3GMQ082PROD with BILLS
61 

HR 5925 RFS 

1 ‘‘(B) activities, functions, projects, or ob2 ject classes. 

3 ‘‘(2) UNAUTHORIZED OBLIGATION OR EXPENDI4 TURE PROHIBITED.—An officer or employee of a 

5 National Drug Control Program Agency shall not 

6 make or authorize an expenditure or obligation con7 trary to a fund control notice issued by the Director. 

8 ‘‘(3) DISCIPLINARY ACTION FOR VIOLATION.— 

9 In the case of a violation of paragraph (2) by an of10 ficer or employee of a National Drug Control Pro11 gram Agency, the head of the agency, upon the re12 quest of and in consultation with the Director, may 

13 subject the officer or employee to appropriate ad14 ministrative discipline, including, when cir15 cumstances warrant, suspension from duty without 

16 pay or removal from office. 

17 ‘‘(4) CONGRESSIONAL NOTICE.—Not later than 

18 5 days after issuance of a fund control notice, the 

19 Director shall submit a copy of such fund control 

20 notice to the appropriate congressional committees 

21 and make such notice publicly available. 

22 ‘‘(5) RESTRICTIONS.—The Director may not 

23 issue a fund control notice to direct that all or part 

24 of an amount appropriated to the National Drug 

25 Control Program Agency account be obligated, modiVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00061 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
62 

HR 5925 RFS 

1 fied, or altered in any manner contrary, in whole or 

2 in part, to a specific appropriation or statute. 

3 ‘‘(f) EXCLUSIONS.—The authorities described under 

4 subsections (c), (d), and (e) do not apply to any program 

5 under subchapter II or III. 

6 ‘‘(g) FOREIGN ASSISTANCE ACT PARTICIPATION.— 

7 The Director may participate in the drug certification 

8 process pursuant to section 490 of the Foreign Assistance 

9 Act of 1961 (22 U.S.C. 2291j) and section 706 of the 

10 Department of State Authorization Act for Fiscal Year 

11 2003 (22 U.S.C. 229j–l). 

12 ‘‘(h) CERTIFICATIONS OF POLICY CHANGES TO DI13 RECTOR.— 

14 ‘‘(1) IN GENERAL.—Subject to paragraph (2), 

15 the head of a National Drug Control Program Agen16 cy shall, unless exigent circumstances require other17 wise, notify the Director in writing regarding any 

18 proposed change in policies relating to the activities 

19 of that agency under the National Drug Control 

20 Program prior to implementation of such change. 

21 The Director shall promptly review such proposed 

22 change and certify to the head of that agency in 

23 writing whether such change is consistent with the 

24 National Drug Control Strategy. 


sradovich on DSK3GMQ082PROD with BILLS
63 

HR 5925 RFS 

1 ‘‘(2) EXCEPTION.—If prior notice of a proposed 

2 change under paragraph (1) is not practicable— 

3 ‘‘(A) the head of the National Drug Con4 trol Program Agency shall notify the Director 

5 of the proposed change as soon as practicable; 

6 and 

7 ‘‘(B) upon such notification, the Director 

8 shall review the change and certify to the head 

9 of that agency in writing whether the change is 

10 consistent with the National Drug Control 

11 Strategy. 

12 ‘‘(i) WORK IN CONJUNCTION WITH ASSISTANT FOR

13 NATIONAL SECURITY AFFAIRS.—The Director shall, in 

14 any matter affecting national security interests, work in 

15 conjunction with the Assistant to the President for Na16 tional Security Affairs. 

17 ‘‘(j) AUTHORITIES NOT DEROGATED.—Nothing in 

18 this chapter shall be construed as derogating the authori19 ties and responsibilities of the head of any agency, the Di20 rector of National Intelligence, or the Director of the Cen21 tral Intelligence Agency contained in the National Security 

22 Act of 1947 (50 U.S.C. 401 et seq.), the Central Intel23 ligence Agency Act of 1949 (50 U.S.C. 403a et seq.), or 

24 any other law. 


sradovich on DSK3GMQ082PROD with BILLS
64 

HR 5925 RFS 

1 ‘‘§ 1009. Emerging threats task force, plan, campaign 

2 ‘‘(a) EMERGING THREATS TASK FORCE.— 

3 ‘‘(1) EMERGING AND CONTINUING THREATS CO4 ORDINATOR.—The Director shall designate or ap5 point a United States Emerging and Continuing 

6 Threats Coordinator to perform the duties of that 

7 position described in this section and such other du8 ties as may be determined by the Director. The Di9 rector shall determine whether the coordinator posi10 tion is a noncareer appointee in the Senior Executive 

11 Service or a career appointee at the GS–15 level (or 

12 equivalent) or above. 

13 ‘‘(2) ESTABLISHMENT AND MONITORING.—The 

14 Emerging and Continuing Threats Coordinator (re15 ferred to in this section as the ‘Coordinator’) shall 

16 monitor evolving and emerging drug threats in the 

17 United States and shall serve as Chair of an Emerg18 ing Threats Task Force (in this section, referred to 

19 as the ‘task force’). The Director shall appoint other 

20 members of the task force, which shall include— 

21 ‘‘(A) representatives from National Drug 

22 Control Program Agencies or other agencies; 

23 ‘‘(B) representatives from State, local, and 

24 Tribal governments; 


sradovich on DSK3GMQ082PROD with BILLS
65 

HR 5925 RFS 

1 ‘‘(C) the Director of the National Drug 

2 Control Fusion Center established in section 

3 1013; and 

4 ‘‘(D) representatives from other entities as 

5 determined to be necessary by the Director. 

6 ‘‘(3) INFORMATION REVIEW AND SHARING.— 

7 ‘‘(A) IN GENERAL.—The task force shall 

8 disseminate and facilitate the sharing with Fed9 eral, State, local, and Tribal officials and other 

10 entities as determined by the Director of perti11 nent information and data relating to the fol12 lowing: 

13 ‘‘(i) Recent trends in drug supply and 

14 demand. 

15 ‘‘(ii) Fatal and nonfatal overdoses. 

16 ‘‘(iii) Demand for and availability of 

17 evidence-based substance use disorder 

18 treatment, including the extent of the 

19 unmet treatment need, and treatment ad20 mission trends. 

21 ‘‘(iv) Recent trends in drug interdic22 tion, supply, and demand from State, local, 

23 and Tribal law enforcement agencies. 

24 ‘‘(v) Other subject matter as deter25 mined necessary by the Director. 


sradovich on DSK3GMQ082PROD with BILLS
66 

HR 5925 RFS 

1 ‘‘(B) CONTRACT, AGREEMENT, AND OTHER

2 AUTHORITY.—The Director may award con3 tracts, enter into interagency agreements, man4 age individual projects, and conduct other ac5 tivities in support of the identification of emerg6 ing drug threats and in support of the develop7 ment, implementation, and assessment of any 

8 Emerging Threat Response Plan. 

9 ‘‘(C) DATA ANALYSIS ACTIVITIES.—In sup10 port of the task force, the National Drug Con11 trol Fusion Center is authorized to conduct and 

12 provide to the task force the results of data 

13 analysis activities that the task force requests 

14 to aid in their review of recent trends in the 

15 data disseminated under subparagraph (A). 

16 ‘‘(4) CRITERIA TO IDENTIFY EMERGING DRUG

17 THREATS.—Not later than 60 days after the date on 

18 which a task force first meets, the task force shall 

19 develop and recommend to the Director criteria to be 

20 used to identify an emerging drug threat or the ter21 mination of an emerging drug threat designation 

22 based on information gathered by the task force in 

23 paragraph (2), statistical data, and other evidence. 

24 ‘‘(5) MEETINGS.—The task force shall meet in 

25 person not less frequently than quarterly and at adVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00066 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
67 

HR 5925 RFS 

1 ditional meetings if determined to be necessary by 

2 and at the call of the Chair to— 

3 ‘‘(A) identify and discuss evolving and 

4 emerging drug trends in the United States 

5 using the criteria established in paragraph (3); 

6 ‘‘(B) assist in the formulation of any plan 

7 described in subsection (c); 

8 ‘‘(C) oversee implementation of the plan 

9 described in subsection (c); and 

10 ‘‘(D) provide such other advice to the Co11 ordinator and Director concerning strategy and 

12 policies for emerging drug threats and trends as 

13 the task force determines to be appropriate. 

14 ‘‘(b) DESIGNATION.— 

15 ‘‘(1) IN GENERAL.—The Director, in consulta16 tion with the Coordinator, the task force, and the 

17 head of each National Drug Control Program Agen18 cy, may designate an emerging drug threat in the 

19 United States. 

20 ‘‘(2) STANDARDS FOR DESIGNATION.—The Di21 rector, in consultation with the Coordinator, shall 

22 promulgate and make publicly available standards by 

23 which a designation under paragraph (1) and the 

24 termination of such designation may be made. In de25 veloping such standards, the Director shall consider 


sradovich on DSK3GMQ082PROD with BILLS
68 

HR 5925 RFS 

1 the recommendations of the task force and other cri2 teria the Director considers to be appropriate. 

3 ‘‘(3) PUBLIC STATEMENT REQUIRED.—The Di4 rector shall publish a public written statement on 

5 the portal of the Office explaining the designation of 

6 an emerging drug threat or the termination of such 

7 designation and shall notify the appropriate congres8 sional committees of the availability of such state9 ment when a designation or termination of such des10 ignation has been made. 

11 ‘‘(c) PLAN.— 

12 ‘‘(1) PUBLIC AVAILABILITY OF PLAN.—Not 

13 later than 60 days after making a designation under 

14 subsection (b), the Director shall publish and make 

15 publicly available an Emerging Threat Response 

16 Plan and notify the President and the appropriate 

17 congressional committees of such plan’s availability. 

18 ‘‘(2) TIMING.—Not less frequently than every 

19 90 days after the date on which the plan is pub20 lished under paragraph (1), the Director shall up21 date the plan and report on implementation of the 

22 plan, until the Director issues the public statement 

23 required under subsection (b)(3) to terminate the 

24 emerging drug threat designation. 


sradovich on DSK3GMQ082PROD with BILLS
69 

HR 5925 RFS 

1 ‘‘(3) CONTENTS OF AN EMERGING THREAT RE2 SPONSE PLAN.—The Director shall include in the 

3 plan— 

4 ‘‘(A) a comprehensive strategic assessment 

5 of the emerging drug threat, including the cur6 rent availability of, demand for, and effective7 ness of evidence-based prevention, treatment, 

8 and enforcement programs and efforts to re9 spond to the emerging drug threat; 

10 ‘‘(B) comprehensive, research-based, long11 range, quantifiable goals for addressing the 

12 emerging drug threat, including for reducing 

13 the supply of the drug designated as the emerg14 ing drug threat and for expanding the avail15 ability and effectiveness of evidence-based sub16 stance use disorder treatment and prevention 

17 programs to reduce the demand for the emerg18 ing drug threat; 

19 ‘‘(C) performance measures pertaining to 

20 the plan’s goals, including quantifiable and 

21 measurable objectives and specific targets; 

22 ‘‘(D) the level of funding needed to imple23 ment the plan, including whether funding is 

24 available to be reprogrammed or transferred to 

25 support implementation of the plan or whether 


sradovich on DSK3GMQ082PROD with BILLS
70 

HR 5925 RFS 

1 additional appropriations are necessary to im2 plement the plan; 

3 ‘‘(E) an implementation strategy for the 

4 education and public awareness campaign under 

5 subsection (d), including goals as described 

6 under subparagraph (B) and performance 

7 measures, objectives, and targets, as described 

8 under subparagraph (C); and 

9 ‘‘(F) any other information necessary to 

10 inform the public of the status, progress, or re11 sponse of an emerging drug threat. 

12 ‘‘(4) IMPLEMENTATION.— 

13 ‘‘(A) IN GENERAL.—Not later than 90 

14 days after the date on which a designation is 

15 made under subsection (b), the Director, in 

16 consultation with the President, the appropriate 

17 congressional committees, and the head of each 

18 National Drug Control Program Agency, shall 

19 issue guidance on implementation of the plan 

20 described in this subsection to the National 

21 Drug Control Program Agencies and any other 

22 relevant agency determined to be necessary by 

23 the Director. 

24 ‘‘(B) COORDINATOR’S RESPONSIBIL25 ITIES.—The Coordinator shall— 


sradovich on DSK3GMQ082PROD with BILLS
71 

HR 5925 RFS 

1 ‘‘(i) direct the implementation of the 

2 plan among the agencies identified in the 

3 plan, State, local, and Tribal governments, 

4 and other relevant entities; 

5 ‘‘(ii) facilitate information-sharing be6 tween agencies identified in the plan, 

7 State, local, and Tribal governments, and 

8 other relevant entities; and 

9 ‘‘(iii) monitor implementation of the 

10 plan by coordinating the development and 

11 implementation of collection and reporting 

12 systems to support performance measure13 ment and adherence to the plan by agen14 cies identified in plan, where appropriate. 

15 ‘‘(C) REPORTING.—Not later than 180 

16 days after the date on which a designation is 

17 made under subsection (b) and in accordance 

18 with paragraph (2)(C), the head of each agency 

19 identified in the plan shall submit to the Coor20 dinator a report on implementation of the plan. 

21 ‘‘(d) EDUCATION AND PUBLIC AWARENESS CAM22 PAIGN FOR EMERGING DRUG THREATS.— 

23 ‘‘(1) IN GENERAL.—Not later than 90 days 

24 after the date on which a designation is made under 

25 subsection (b), the Director shall, to the extent feaVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00071 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
72 

HR 5925 RFS 

1 sible and appropriate, establish and implement an 

2 evidence-based substance use prevention education 

3 and public awareness campaign to inform the public 

4 about the dangers of any drug designated as an 

5 emerging drug threat. Such campaign shall— 

6 ‘‘(A) educate the public about the dangers 

7 of such drug, including patient and family edu8 cation about the characteristics and hazards of 

9 such drug and methods to safeguard against 

10 such dangers, including the safe disposal of 

11 such drug; 

12 ‘‘(B) support evidence-based prevention 

13 programs targeting audiences’ attitudes, percep14 tions, and beliefs concerning substance use and 

15 intentions to initiate or continue such use; 

16 ‘‘(C) increase awareness of the negative 

17 consequences of drug use; 

18 ‘‘(D) encourage individuals affected by 

19 substance use disorders to seek treatment and 

20 provide such individuals with information on 

21 how to recognize addiction issues, what forms 

22 of evidence-based treatment options are avail23 able, and how to access such treatment; and 

24 ‘‘(E) combat the stigma of addiction and 

25 substance use disorders, including the stigma of 


sradovich on DSK3GMQ082PROD with BILLS
73 

HR 5925 RFS 

1 treating such disorders with medication-assisted 

2 treatment therapies. 

3 ‘‘(2) CONSULTATION.—For the planning of the 

4 campaign under paragraph (1), the Director shall 

5 consult with— 

6 ‘‘(A) the head of any appropriate National 

7 Drug Control Program Agency to obtain advice 

8 on evidence-based scientific information for pol9 icy, program development, and evaluation; 

10 ‘‘(B) experts in evidence-based media cam11 paigns, education, evaluation, and communica12 tion; 

13 ‘‘(C) experts on the designated drug; 

14 ‘‘(D) State, local, and Tribal government 

15 officials and relevant agencies; 

16 ‘‘(E) the public; 

17 ‘‘(F) appropriate congressional committees; 

18 and 

19 ‘‘(G) any other affected person, as deter20 mined by the Director. 

21 ‘‘(3) GIFTS AND DONATIONS.— 

22 ‘‘(A) IN GENERAL.—The Director may ac23 cept gifts and donations (in cash or in kind, in24 cluding voluntary and uncompensated services 

25 or property), which shall be available until exVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00073 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
74 

HR 5925 RFS 

1 pended, for the purpose of supporting the edu2 cation and public awareness campaign author3 ized in this section, including the media cam4 paign. 

5 ‘‘(B) ETHICS GUIDELINES.—The Director 

6 shall establish written guidelines setting forth 

7 the criteria to be used in determining whether 

8 a gift or donation should be declined under this 

9 section because the acceptance of the gift or do10 nation would— 

11 ‘‘(i) reflect unfavorably upon the abil12 ity of the Director or the Office, or any 

13 employee of the Office, to carry out re14 sponsibilities or official duties under this 

15 chapter in a fair and objective manner; or 

16 ‘‘(ii) compromise the integrity or the 

17 appearance of integrity of programs or 

18 services provided under this chapter or of 

19 any official involved in those programs or 

20 services. 

21 ‘‘(4) IMPLEMENTATION.— 

22 ‘‘(A) IN GENERAL.—For any campaign es23 tablished under this subsection, the Director 

24 shall ensure the following: 


sradovich on DSK3GMQ082PROD with BILLS
75 

HR 5925 RFS 

1 ‘‘(i) Implementation is evidence-based, 

2 meets accepted standards for public aware3 ness campaigns, and uses available re4 sources in a manner to make the most 

5 progress toward achieving the goals identi6 fied in the Emerging Threats Response 

7 Plan and the requirements of paragraph 

8 (1). 

9 ‘‘(ii) Information disseminated 

10 through the campaign is accurate. 

11 ‘‘(iii) The Director approves the strat12 egy of the campaign, all material distrib13 uted through the campaign, and the use of 

14 any Federal funds used for the campaign. 

15 ‘‘(iv) The campaign is designed using 

16 strategies found to be most effective at 

17 achieving such goals and requirements of 

18 paragraph (1), which may include— 

19 ‘‘(I) a media campaign, as de20 scribed in subparagraph (B); 

21 ‘‘(II) local, regional, or popu22 lation specific messaging; 

23 ‘‘(III) establishing partnerships 

24 and promoting coordination among 

25 community stakeholders, including 


sradovich on DSK3GMQ082PROD with BILLS
76 

HR 5925 RFS 

1 public, nonprofit organizations, and 

2 for profit entities; 

3 ‘‘(IV) providing support, train4 ing, and technical assistance to estab5 lish and expand school and commu6 nity prevention programs; 

7 ‘‘(V) creating websites to pub8 licize and disseminate information; 

9 ‘‘(VI) conducting outreach and 

10 providing educational resources for 

11 parents; 

12 ‘‘(VII) establishing State or re13 gional advisory councils to provide 

14 input and recommendations to raise 

15 awareness regarding the drug des16 ignated as an emerging drug threat; 

17 ‘‘(VIII) collaborating with law 

18 enforcement; and 

19 ‘‘(IX) support for school-based 

20 public health education classes to im21 prove teen knowledge about the effects 

22 of such designated drug. 

23 ‘‘(B) MEDIA CAMPAIGN.—Any campaign 

24 implemented under this subsection may include 

25 a media component, which— 


sradovich on DSK3GMQ082PROD with BILLS
77 

HR 5925 RFS 

1 ‘‘(i) shall be designed to prevent the 

2 use of the drug designated as an emerging 

3 drug threat and to achieve the goals and 

4 requirements of paragraph (1); 

5 ‘‘(ii) shall be carried out through com6 petitively awarded contracts to entities pro7 viding for the professional production and 

8 design of such campaign; and 

9 ‘‘(iii) may include the use of tele10 vision, radio, Internet, social media, and 

11 other commercial marketing venues and 

12 may be targeted to specific age groups 

13 based on peer-reviewed social research. 

14 ‘‘(C) REQUIRED NOTICE FOR COMMUNICA15 TION FROM THE OFFICE.—Any communication, 

16 including an advertisement, paid for or other17 wise disseminated by the Office directly or 

18 through a contract awarded by the Office shall 

19 include a prominent notice informing the audi20 ence that the communication was paid for by of 

21 the Office. 

22 ‘‘(5) EVALUATION.— 

23 ‘‘(A) PERFORMANCE EVALUATION.—The 

24 Director shall include an evaluation of the camVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00077 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
78 

HR 5925 RFS 

1 paign in the annual assessment under section 

2 1006, which shall include the following: 

3 ‘‘(i) A performance evaluation of the 

4 campaign, including progress toward meet5 ing the goals, objectives, measures, and 

6 targets identified in the Emerging Threats 

7 Response Plan. 

8 ‘‘(ii) A description of all policies and 

9 practices to eliminate the potential for 

10 waste, fraud, abuse, and to ensure Federal 

11 funds are used responsibly. 

12 ‘‘(iii) A list of all contracts or other 

13 agreements entered into to implement the 

14 campaign. 

15 ‘‘(iv) The results of any financial 

16 audit of the campaign. 

17 ‘‘(v) A description of any evidence 

18 used to develop the campaign. 

19 ‘‘(vi) The sources and amount of each 

20 gift or donation accepted by the Office, 

21 and the source and amount of each gift or 

22 donation accepted by a contractor to be 

23 used in its performance of a contract for 

24 the campaign. 


sradovich on DSK3GMQ082PROD with BILLS
79 

HR 5925 RFS 

1 ‘‘(B) INDEPENDENT EVALUATION.—Not 

2 later than 180 days after establishing a cam3 paign under paragraph (1) and not less than 

4 frequently than every 2 years thereafter, the 

5 Director shall— 

6 ‘‘(i) designate an independent entity 

7 to evaluate the effectiveness of the cam8 paign with meeting the goals established in 

9 the Emerging Threat Response Plan and 

10 the requirements of paragraph (1); and 

11 ‘‘(ii) submit the results of the inde12 pendent evaluation to the appropriate con13 gressional committees. 

14 ‘‘(6) FUNDING PROHIBITIONS.—None of the 

15 amounts made available under this subsection may 

16 be obligated for any of the following: 

17 ‘‘(A) To supplant current anti-drug com18 munity-based coalitions. 

19 ‘‘(B) To supplant pro bono public service 

20 time donated by national and local broadcasting 

21 network for other public services campaigns. 

22 ‘‘(C) For partisan political purposes, or ex23 press advocacy in support of or to defeat any 

24 clearly identified candidate, clearly identified 


sradovich on DSK3GMQ082PROD with BILLS
80 

HR 5925 RFS 

1 ballot initiative, or clearly identified legislative 

2 or regulatory proposal. 

3 ‘‘(D) For any advocacy in support of any 

4 particular company, industry association, or ad5 vocacy group or the explicit policy positions 

6 held by such groups. 

7 ‘‘(E) To direct any individuals to a specific 

8 type of substance use disorder treatment, treat9 ment facility, medical provider, or form of medi10 cation assisted treatment. 

11 ‘‘(F) To fund any advertising that features 

12 any elected officials, persons seeking elected of13 fice, cabinet level officials, or other Federal offi14 cials employed pursuant to section 213 of 

15 Schedule C of title 5, Code of Federal Regula16 tions. 

17 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 

18 is authorized to be appropriated to the Office to carry out 

19 this section, $25 million for each of fiscal years 2019 

20 through 2023. 

21 ‘‘§ 1010. National and international coordination 

22 ‘‘(a) DISSEMINATION OF RESEARCH AND INFORMA23 TION TO STATES.—The Director shall ensure that drug 

24 control research and information is effectively dissemi25 nated by National Drug Control Program Agencies to 


sradovich on DSK3GMQ082PROD with BILLS
81 

HR 5925 RFS 

1 State and local governments and nongovernmental entities 

2 involved in demand reduction by— 

3 ‘‘(1) encouraging formal consultation between 

4 any such agency that conducts or sponsors research, 

5 and any such agency that disseminates information 

6 in developing research and information product de7 velopment agendas; 

8 ‘‘(2) encouraging such agencies (as appropriate) 

9 to develop and implement dissemination plans that 

10 specifically target State and local governments and 

11 nongovernmental entities involved in demand reduc12 tion; and 

13 ‘‘(3) supporting the substance abuse informa14 tion clearinghouse administered by the Assistant 

15 Secretary for Mental Health and Substance Use and 

16 established in section 501(d)(16) of the Public 

17 Health Service Act by— 

18 ‘‘(A) encouraging all National Drug Con19 trol Program Agencies to provide all appro20 priate and relevant information; and 

21 ‘‘(B) supporting the dissemination of infor22 mation to all interested entities. 

23 ‘‘(b) STANDARDS.— 

24 ‘‘(1) DEVELOPMENT.—The Director shall co25 ordinate the development of evidence-based standVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00081 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
82 

HR 5925 RFS 

1 ards developed by National Drug Control Program 

2 Agencies and other relevant agencies and non-Fed3 eral entities to State, local, and Tribal governments 

4 and nongovernmental entities related to drug control 

5 policies, practices, and procedures, such as the inves6 tigation of drug-related deaths, by— 

7 ‘‘(A) encouraging appropriate agencies and 

8 State, local, and Tribal governments to develop 

9 data standards for drug control practices and 

10 procedures and related statistical data; 

11 ‘‘(B) encouraging information sharing be12 tween appropriate agencies and State, local, 

13 and Tribal governments of relevant drug control 

14 information and data; 

15 ‘‘(C) establishing a working group of agen16 cies, State, local, and Tribal governments, and 

17 other relevant stakeholders to discuss and de18 velop such standards; and 

19 ‘‘(D) facilitating collaboration among agen20 cies, non-Federal entities, States, local, and 

21 Tribal governments, and nongovernmental 

22 agencies. 

23 ‘‘(2) IMPLEMENTATION.—The Director shall 

24 promote the implementation of the standards de25 scribed in paragraph (1) by— 


sradovich on DSK3GMQ082PROD with BILLS
83 

HR 5925 RFS 

1 ‘‘(A) encouraging adoption by providing 

2 the standards to State and local governments 

3 through the internet, annual publications or 

4 periodicals, and other widely-disseminated 

5 means; and 

6 ‘‘(B) facilitating the use and dissemination 

7 of such standards among State and local gov8 ernments by— 

9 ‘‘(i) providing technical assistance to 

10 State, local, and Tribal governments seek11 ing to adopt or implement such standards; 

12 and 

13 ‘‘(ii) coordinating seminars and train14 ing sessions for State, local, and Tribal 

15 governments seeking to adopt or imple16 ment such standards. 

17 ‘‘(c) PRIVATE SECTOR.— 

18 ‘‘(1) IN GENERAL.—The Director or the head 

19 of a National Drug Control Program (as designated 

20 by the Director) shall coordinate with the private 

21 sector to promote private research and development 

22 of medications to treat or prevent addiction, includ23 ing research and development for non-addictive pain 

24 management medication, abuse deterrent formula25 tions, medication-assisted treatment, and other adVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00083 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
84 

HR 5925 RFS 

1 diction research determined to be necessary by the 

2 Director by— 

3 ‘‘(A) encouraging the sharing of informa4 tion regarding evidence-based treatment addic5 tion findings and related data between agencies 

6 and the private sector, as appropriate; 

7 ‘‘(B) encouraging collaboration between 

8 appropriate agencies and the private sector; and 

9 ‘‘(C) providing private sector entities with 

10 relevant statistical data and information to en11 hance research as permissible. 

12 ‘‘(2) WORKING GROUP.—The Director may es13 tablish a working group of National Drug Control 

14 Program Agencies, State, local, and Tribal govern15 ments, and the private sector stakeholders to discuss 

16 and disseminate best practices, research and devel17 opment, and other related issues, as appropriate. 

18 ‘‘(d) MODEL ACTS PROGRAM.— 

19 ‘‘(1) IN GENERAL.—The Director shall provide 

20 for or shall enter into an agreement with a nonprofit 

21 organization to— 

22 ‘‘(A) advise States on establishing laws 

23 and policies to address illicit drug use issues; 

24 and 


sradovich on DSK3GMQ082PROD with BILLS
85 

HR 5925 RFS 

1 ‘‘(B) revise such model State drug laws 

2 and draft supplementary model State laws to 

3 take into consideration changes in illicit drug 

4 use issues in the State involved. 

5 ‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 

6 There is authorized to be appropriated to carry out 

7 this subsection $1.25 million for each of fiscal years 

8 2019 through 2023. 

9 ‘‘(e) DRUG COURT TRAINING AND TECHNICAL AS10 SISTANCE PROGRAM.— 

11 ‘‘(1) GRANTS AUTHORIZED.—The Director may 

12 make a grant to a nonprofit organization for the 

13 purpose of providing training and technical assist14 ance to drug courts. 

15 ‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 

16 There is authorized to be appropriated to carry out 

17 this subsection $2 million for each of fiscal years 

18 2019 through 2023. 

19 ‘‘(f) INTERNATIONAL COORDINATION.—The Director 

20 may facilitate international drug control coordination ef21 forts. 

22 ‘‘(g) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI23 NATOR.—The Director shall designate or appoint a United 

24 States State, Local, and Tribal Affairs Coordinator to per25 form the duties of the Office outlined in this section and 


sradovich on DSK3GMQ082PROD with BILLS
86 

HR 5925 RFS 

1 section 1005 and such other duties as may be determined 

2 by the Director with respect to coordination of drug con3 trol efforts between agencies and State, local, and Tribal 

4 governments. The Director shall determine whether the 

5 coordinator position is a noncareer appointee in the Senior 

6 Executive Service or a career appointee at the GS–15 level 

7 (or equivalent) or above. 

8 ‘‘§ 1011. Interdiction 

9 ‘‘(a) UNITED STATES INTERDICTION COORDI10 NATOR.— 

11 ‘‘(1) IN GENERAL.—The Director shall des12 ignate or appoint a noncareer appointee in the Sen13 ior Executive Service or a career appointee at the 

14 GS–15 level (or equivalent) or above as the United 

15 States Interdiction Coordinator to perform the du16 ties of that position described in paragraph (2) and 

17 such other duties as may be determined by the Di18 rector with respect to coordination of efforts to 

19 interdict illicit drugs from entering the United 

20 States. 

21 ‘‘(2) RESPONSIBILITIES.—The United States 

22 Interdiction Coordinator shall be responsible to the 

23 Director for— 

24 ‘‘(A) coordinating the interdiction activities 

25 of the National Drug Control Program AgenVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00086 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
87 

HR 5925 RFS 

1 cies to ensure consistency with the National 

2 Drug Control Strategy; 

3 ‘‘(B) on behalf of the Director, developing 

4 and issuing, on or before September 1 of each 

5 year and in accordance with paragraph (4), a 

6 National Interdiction Command and Control 

7 Plan to ensure the coordination and consistency 

8 described in subparagraph (A); 

9 ‘‘(C) assessing the sufficiency of assets 

10 committed to illicit drug interdiction by the rel11 evant National Drug Control Program Agen12 cies; and 

13 ‘‘(D) advising the Director on the efforts 

14 of each National Drug Control Program Agency 

15 to implement the National Interdiction Com16 mand and Control Plan. 

17 ‘‘(3) STAFF.—The Director shall assign such 

18 permanent staff of the Office as he considers appro19 priate to assist the United States Interdiction Coor20 dinator to carry out the responsibilities described in 

21 paragraph (2), and may request that appropriate 

22 National Drug Control Program Agencies detail or 

23 assign staff to assist in carrying out such activities. 

24 ‘‘(4) NATIONAL INTERDICTION COMMAND AND

25 CONTROL PLAN.— 


sradovich on DSK3GMQ082PROD with BILLS
88 

HR 5925 RFS 

1 ‘‘(A) PURPOSES.—The National Interdic2 tion Command and Control Plan— 

3 ‘‘(i) shall set forth the Government’s 

4 strategy for drug interdiction; 

5 ‘‘(ii) shall state the specific roles and 

6 responsibilities of the relevant National 

7 Drug Control Program Agencies for imple8 menting that strategy; and 

9 ‘‘(iii) shall identify the specific re10 sources required to enable the relevant Na11 tional Drug Control Program Agencies to 

12 implement that strategy. 

13 ‘‘(B) CONSULTATION WITH OTHER AGEN14 CIES.—Before the submission of the National 

15 Drug Control Strategy or annual supplement 

16 required under section 1005(d), as applicable, 

17 the United States Interdiction Coordinator shall 

18 issue the National Interdiction Command and 

19 Control Plan, in consultation with the other 

20 members of the Interdiction Committee de21 scribed in subsection (b). 

22 ‘‘(C) REPORT TO CONGRESS.—On or be23 fore September 1 of each year, the Director, 

24 through the United States Interdiction Coordi25 nator, shall provide to the appropriate congresVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00088 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
89 

HR 5925 RFS 

1 sional committees, to the Committee on Armed 

2 Services and the Committee on Homeland Secu3 rity of the House of Representatives, and to the 

4 Committee on Homeland Security and Govern5 mental Affairs and the Committee on Armed 

6 Services of the Senate, a report that— 

7 ‘‘(i) includes— 

8 ‘‘(I) a copy of that year’s Na9 tional Interdiction Command and 

10 Control Plan; 

11 ‘‘(II) information for the previous 

12 10 years regarding the number and 

13 type of seizures of drugs by each Na14 tional Drug Control Program Agency 

15 conducting drug interdiction activities 

16 and statistical information on the geo17 graphic areas of such seizures; and 

18 ‘‘(III) information for the pre19 vious 10 years regarding the number 

20 of air and maritime patrol hours un21 dertaken by each National Drug Con22 trol Program Agency conducting drug 

23 interdiction activities and statistical 

24 information on the geographic areas 


sradovich on DSK3GMQ082PROD with BILLS
90 

HR 5925 RFS 

1 in which such patrol hours took place; 

2 and 

3 ‘‘(ii) may include recommendations 

4 about changes to existing agency authori5 ties or laws governing interagency relation6 ships. 

7 ‘‘(D) CLASSIFIED ANNEX.—The report 

8 submitted pursuant to subparagraph (C) may 

9 include a classified annex. 

10 ‘‘(b) INTERDICTION COMMITTEE.— 

11 ‘‘(1) IN GENERAL.—The Interdiction Com12 mittee shall meet to— 

13 ‘‘(A) discuss and resolve issues related to 

14 the coordination, oversight, and integration of 

15 international, border, and domestic drug inter16 diction efforts in support of the National Drug 

17 Control Strategy; 

18 ‘‘(B) review the annual National Interdic19 tion Command and Control Plan, and provide 

20 advice to the Director and the United States 

21 Interdiction Coordinator concerning that plan; 

22 and 

23 ‘‘(C) provide such other advice to the Di24 rector concerning drug interdiction strategy and 


sradovich on DSK3GMQ082PROD with BILLS
91 

HR 5925 RFS 

1 policies as the committee determines is appro2 priate. 

3 ‘‘(2) CHAIR.—The Director shall designate one 

4 of the members of the Interdiction Committee to 

5 serve as Chair. 

6 ‘‘(3) MEETINGS.—The members of the Interdic7 tion Committee shall meet, in person and not 

8 through any delegate or representative, at least once 

9 per calendar year, before June 1. At the call of the 

10 Director or the Chair, the Interdiction Committee 

11 may hold additional meetings, which shall be at12 tended by the members in person, or through such 

13 delegates or representatives as the members may 

14 choose. 

15 ‘‘(4) REPORT.—Not later than September 30 of 

16 each year, the Chair of the Interdiction Committee 

17 shall submit to the Director and to the appropriate 

18 congressional committees a report describing the re19 sults of the meetings and any significant findings of 

20 the committee during the previous 12 months. Such 

21 report may include a classified annex. 

22 ‘‘§ 1012. Treatment coordinator 

23 ‘‘(a) UNITED STATES TREATMENT COORDINATOR.— 

24 ‘‘(1) IN GENERAL.—The Director shall des25 ignate or appoint a noncareer appointee in the SenVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00091 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
92 

HR 5925 RFS 

1 ior Executive Service or a career appointee at the 

2 GS–15 level (or equivalent) or above as the United 

3 States Treatment Coordinator to perform the re4 sponsibilities of that position described in paragraph 

5 (2) and such other duties as may be determined by 

6 the Director with respect to coordination of efforts 

7 to expand the availability of substance use disorder 

8 treatment with the goal of eliminating the unmet 

9 treatment need. 

10 ‘‘(2) RESPONSIBILITIES.—The United States 

11 Treatment Coordinator shall be responsible to the 

12 Director for— 

13 ‘‘(A) coordinating the activities of the Na14 tional Drug Control Program Agencies under15 taken to expand the availability of evidence16 based substance use disorder treatment to en17 sure consistency with the National Drug Con18 trol Strategy; 

19 ‘‘(B) on behalf of the Director, developing 

20 and issuing, on or before September 1 of each 

21 year and in accordance with paragraph (4), a 

22 National Treatment Plan to ensure the coordi23 nation and consistency described in subpara24 graph (A); 


sradovich on DSK3GMQ082PROD with BILLS
93 

HR 5925 RFS 

1 ‘‘(C) assessing the sufficiency of Federal 

2 resources directed to substance use disorder 

3 treatment by the relevant National Drug Con4 trol Program Agencies; 

5 ‘‘(D) encouraging the adoption by all sub6 stance use disorder treatment providers of evi7 dence-based standards to guide all aspects of 

8 treatment provided; and 

9 ‘‘(E) advising the Director on the efforts 

10 of each National Drug Control Program Agency 

11 to implement the National Treatment Plan. 

12 ‘‘(3) STAFF.—The Director shall assign such 

13 permanent staff of the Office of the United States 

14 Treatment Coordinator as the Director determines 

15 to be appropriate to assist the United States Treat16 ment Coordinator to carry out the responsibilities 

17 described in paragraph (2), and may request that 

18 appropriate National Drug Control Program Agen19 cies detail or assign staff to assist in carrying out 

20 such responsibilities. 

21 ‘‘(4) NATIONAL TREATMENT PLAN.— 

22 ‘‘(A) PURPOSES.—The National Treatment 

23 Plan— 

24 ‘‘(i) shall identify the unmet need for 

25 treatment for evidence-based substance use 


sradovich on DSK3GMQ082PROD with BILLS
94 

HR 5925 RFS 

1 disorders and set forth the Government’s 

2 strategy for closing the gap between avail3 able and needed treatment through all 

4 sources; 

5 ‘‘(ii) shall describe the specific roles 

6 and responsibilities of the relevant Na7 tional Drug Control Program Agencies for 

8 implementing that strategy; 

9 ‘‘(iii) shall identify the specific re10 sources required to enable the relevant Na11 tional Drug Control Program Agencies to 

12 implement that strategy; 

13 ‘‘(iv) shall identify the resources, in14 cluding private sources, required to elimi15 nate the unmet need for evidence-based 

16 substance use disorder treatment; and 

17 ‘‘(v) may include recommendations 

18 about changes to existing agency authori19 ties or laws governing interagency relation20 ships. 

21 ‘‘(B) CONSULTATION WITH OTHER AGEN22 CIES.—Before the submission of the National 

23 Treatment Strategy or annual supplement re24 quired under section 1005(d), as applicable, the 

25 United States Treatment Coordinator shall 


sradovich on DSK3GMQ082PROD with BILLS
95 

HR 5925 RFS 

1 issue the National Treatment Plan, in consulta2 tion with the other members of the Treatment 

3 Committee described in subsection (b). 

4 ‘‘(C) REPORT TO CONGRESS.—On or be5 fore September 1 of each year, the Director, 

6 through the United States Treatment Coordi7 nator, shall provide to the appropriate congres8 sional committees a report that includes a copy 

9 of that year’s National Treatment Plan. 

10 ‘‘(b) TREATMENT COMMITTEE.— 

11 ‘‘(1) IN GENERAL.—The Treatment Committee 

12 shall meet to— 

13 ‘‘(A) review and discuss the adequacy of 

14 evidence-based substance use disorder treat15 ment as well as the unmet need for treatment; 

16 ‘‘(B) review and discuss the status of the 

17 implementation of the National Treatment 

18 Plan; and 

19 ‘‘(C) provide such other advice to the Di20 rector concerning substance use disorder treat21 ment initiatives as the committee determines is 

22 appropriate. 

23 ‘‘(2) CHAIR.—The Director shall designate one 

24 of the members of the Treatment Committee to 

25 serve as Chair. 


sradovich on DSK3GMQ082PROD with BILLS
96 

HR 5925 RFS 

1 ‘‘(3) MEETINGS.—The members of the Treat2 ment Committee shall meet, in person and not 

3 through any delegate or representative, at least once 

4 per calendar year, before June 1. At the call of the 

5 Director or the Chair, the Treatment Committee 

6 may hold additional meetings, which shall be at7 tended by the members in person, or through such 

8 delegates or representatives as the members may 

9 choose. 

10 ‘‘(4) REPORT.—Not later than September 30 of 

11 each year, the Chair of the Treatment Committee 

12 shall submit to the Director and to the appropriate 

13 congressional committees a report describing the re14 sults of the meetings and any significant findings of 

15 the committee during the previous 12 months. Such 

16 report may include a classified annex. 

17 ‘‘§ 1013. Critical information coordination 

18 ‘‘(a) NATIONAL DRUG CONTROL FUSION CENTER.— 

19 ‘‘(1) ESTABLISHMENT.—The Director shall, in 

20 consultation with the head of each National Drug 

21 Control Program Agency, designate an agency to es22 tablish a National Drug Control Fusion Center (re23 ferred to in this section as the ‘Center’). The Center 

24 shall operate under the authority of the Director and 

25 shall work with the National Drug Control Program 


sradovich on DSK3GMQ082PROD with BILLS
97 

HR 5925 RFS 

1 Agencies to collect, compile, analyze, and facilitate 

2 the sharing of data on the use of illicit drugs, treat3 ment for substance use disorder, and interdiction of 

4 illicit drugs. The Center shall be considered a ‘statis5 tical agency or unit’, as that term is defined in sec6 tion 502 of the Confidential Information Protection 

7 and Statistical Efficiency Act of 2002 (44 U.S.C. 

8 3501 note) and shall have the necessary independ9 ence to ensure any data or information acquired by 

10 an agency under a pledge of confidentiality and for 

11 exclusively statistical purposes is used exclusively for 

12 statistical purposes. 

13 ‘‘(2) CENTER DIRECTOR.—There shall be at the 

14 head of the Center a Center Director who shall be 

15 appointed by the Director from among individuals 

16 qualified and distinguished in data governance and 

17 statistical analysis. 

18 ‘‘(3) DATA COMPILATION.—The Director, act19 ing through the Center Director, shall do the fol20 lowing: 

21 ‘‘(A) Coordinate data collection activities 

22 among the National Drug Control Program 

23 Agencies. 

24 ‘‘(B) Collect information not otherwise col25 lected by National Drug Control Program 


sradovich on DSK3GMQ082PROD with BILLS
98 

HR 5925 RFS 

1 Agencies as necessary to inform the National 

2 Drug Control Strategy. 

3 ‘‘(C) Compile and analyze any data re4 quired to be collected under this chapter. 

5 ‘‘(D) Disseminate technology, as appro6 priate, to States and local jurisdictions to en7 able or improve the collection of data on drug 

8 use, including the recordation of the occurrence 

9 of fatal and non-fatal drug overdoses. 

10 ‘‘(E) Compile information collected by Na11 tional Drug Control Program Agencies on 

12 grants issued through any National Drug Con13 trol Program, including for any grant the fol14 lowing: 

15 ‘‘(i) The recipient. 

16 ‘‘(ii) The amount. 

17 ‘‘(iii) The intended purpose. 

18 ‘‘(iv) Any evidence of the efficacy of 

19 the outcomes achieved by the program 

20 funded through the grant. 

21 ‘‘(v) Any assessments of how the 

22 grant met its intended purpose. 

23 ‘‘(4) TOXICOLOGY SCREENING.— 


sradovich on DSK3GMQ082PROD with BILLS
99 

HR 5925 RFS 

1 ‘‘(A) ESTABLISHMENT.—The Center Di2 rector may establish a toxicology screening pro3 gram that engages in— 

4 ‘‘(i) secondary analysis of urine sam5 ples that would otherwise be discarded 

6 by— 

7 ‘‘(I) hospitals and substance use 

8 disorder treatment programs; 

9 ‘‘(II) correctional facilities, book10 ing sites, probation programs, drug 

11 courts, and related facilities; and 

12 ‘‘(III) coroners and medical ex13 aminers; and 

14 ‘‘(ii) analysis of other physical sam15 ples, as determined by the Center Director 

16 to be valuable for understanding the preva17 lence of any illicit drug. 

18 ‘‘(B) DE-IDENTIFICATION OF INFORMA19 TION.—The Center Director shall ensure that 

20 no samples have any personally identifiable in21 formation prior to collection. 

22 ‘‘(C) LIMITATION ON USE.—No data ob23 tained from analysis conducted under this para24 graph may be used as evidence in any pro25 ceeding. 


sradovich on DSK3GMQ082PROD with BILLS
100 

HR 5925 RFS 

1 ‘‘(D) STATE PROGRAM.—The Center Di2 rector may establish a program that enables 

3 States and local jurisdictions to submit up to 

4 20 urine samples per year for toxicology anal5 ysis for the purposes of identifying substances 

6 present in individuals who have suffered fatal 

7 drug overdoses. 

8 ‘‘(5) AUTHORITY TO CONTRACT.—The Director 

9 may award contracts, enter into interagency agree10 ments, manage individual projects, and conduct 

11 other operational activities under this subsection. 

12 ‘‘(b) CRITICAL DRUG CONTROL INFORMATION AND

13 EVIDENCE PLAN.— 

14 ‘‘(1) IN GENERAL.—Not later than the first 

15 Monday in February of each year, the Director shall 

16 submit to Congress a systematic plan for increasing 

17 data collection to enable real-time surveillance of 

18 drug control threats, developing analysis and moni19 toring capabilities, and identifying and addressing 

20 policy questions relevant to the National Drug Con21 trol Policy, Strategy, and Program. Such plan shall 

22 be made available on the public online portal of the 

23 Office, shall cover at least a 4-year period beginning 

24 with the first fiscal year following the fiscal year in 


sradovich on DSK3GMQ082PROD with BILLS
101 

HR 5925 RFS 

1 which the plan is submitted and published, and con2 tain the following: 

3 ‘‘(A) A list of policy-relevant questions for 

4 which the Director and each National Drug 

5 Control Program Agency intends to develop evi6 dence to support the National Drug Control 

7 Program and Strategy. 

8 ‘‘(B) A list of data the Director and each 

9 National Drug Control Program Agency intends 

10 to collect, use, or acquire to facilitate the use of 

11 evidence in drug control policymaking and mon12 itoring. 

13 ‘‘(C) A list of methods and analytical ap14 proaches that may be used to develop evidence 

15 to support the National Drug Control Program 

16 and Strategy and related policy. 

17 ‘‘(D) A list of any challenges to developing 

18 evidence to support policymaking, including any 

19 barriers to accessing, collecting, or using rel20 evant data. 

21 ‘‘(E) A description of the steps the Direc22 tor and the head of each National Drug Control 

23 Program Agency will take to effectuate the 

24 plan. 


sradovich on DSK3GMQ082PROD with BILLS
102 

HR 5925 RFS 

1 ‘‘(F) Any other relevant information as de2 termined by the Director. 

3 ‘‘(2) CONSULTATION.—In developing the plan 

4 required under paragraph (1), the Director shall 

5 consult with the following: 

6 ‘‘(A) The public. 

7 ‘‘(B) Any evaluation or analysis units and 

8 personnel of the Office. 

9 ‘‘(C) Office officials responsible for imple10 menting privacy policy. 

11 ‘‘(D) Office officials responsible for data 

12 governance. 

13 ‘‘(E) The appropriate congressional com14 mittees. 

15 ‘‘(F) Any other individual or entity as de16 termined by the Director. 

17 ‘‘(c) EVIDENCE-BASED POLICY.— 

18 ‘‘(1) HARM REDUCTION PROGRAMS.—When de19 veloping the national drug control policy, any policy 

20 of the Director, including policies relating to syringe 

21 exchange programs for intravenous drug users, shall 

22 be based on the best available medical and scientific 

23 evidence regarding the effectiveness of such policy in 

24 promoting individual health, preventing the spread 

25 of infectious disease and the impact of such policy 


sradovich on DSK3GMQ082PROD with BILLS
103 

HR 5925 RFS 

1 on drug addiction and use. In making any policy re2 lating to harm reduction programs, the Director 

3 shall consult with the National Institutes of Health 

4 and the National Academy of Sciences. 

5 ‘‘(2) FUND RESTRICTION FOR THE LEGALIZA6 TION OF CONTROLLED SUBSTANCES.—The Director 

7 shall ensure that no Federal funds appropriated to 

8 the Office shall be expended for any study or con9 tract relating to the legalization (for a medical use 

10 or any other use) for which a listing in schedule I 

11 is in effect under section 202 of the Controlled Sub12 stances Act (21 U.S.C. 812). 

13 ‘‘(d) DRUG CONTROL DATA DASHBOARD.— 

14 ‘‘(1) ESTABLISHMENT.—The Director, in con15 sultation with the Center Director, shall establish 

16 and maintain a data dashboard on the online portal 

17 of the Office to be known as the ‘Drug Control Data 

18 Dashboard’. The Director shall ensure the user 

19 interface of the dashboard is constructed with mod20 ern design standards. To the extent practicable, the 

21 data made available on the dashboard shall be pub22 licly available in a machine-readable format and 

23 searchable by year, agency, drug, and location. 

24 ‘‘(2) DATA.—The data included in the Drug 

25 Control Data Dashboard shall be updated quarterly 


sradovich on DSK3GMQ082PROD with BILLS
104 

HR 5925 RFS 

1 to the extent practicable, but not less frequently 

2 than annually and shall include, at a minimum, the 

3 following: 

4 ‘‘(A) For each substance identified under 

5 section 1005(c)(1)(A)(i)— 

6 ‘‘(i) the total amount seized and dis7 rupted in the calendar year and each of 

8 the previous 3 calendar years, including to 

9 the extent practicable the amount seized by 

10 State, local, and Tribal governments; 

11 ‘‘(ii) the known and estimated flows 

12 into the United States from all sources in 

13 the calendar year and each of the previous 

14 3 calendar years; 

15 ‘‘(iii) the total amount of known flows 

16 that could not be interdicted or disrupted 

17 in the calendar year and each of the pre18 vious 3 calendar years; 

19 ‘‘(iv) the known and estimated levels 

20 of domestic production in the calendar year 

21 and each of the previous 3 calendar years, 

22 including the levels of domestic production 

23 if the drug is a prescription drug, as deter24 mined under the Federal Food, Drug, and 

25 Cosmetic Act, for which a listing is in efVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00104 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
105 

HR 5925 RFS 

1 fect under section 202 of the Controlled 

2 Substances Act (21 U.S.C. 812); 

3 ‘‘(v) the average street price for the 

4 calendar year and the highest known street 

5 price during the preceding 10-year period; 

6 and 

7 ‘‘(vi) to the extent practicable, related 

8 prosecutions by State, local, and Tribal 

9 governments. 

10 ‘‘(B) For the calendar year and each of the 

11 previous 3 years data sufficient to show, 

12 disaggregated by State and, to the extent fea13 sible, by region within a State, county, or city, 

14 the following: 

15 ‘‘(i) The number of fatal and non16 fatal overdoses caused by each drug identi17 fied under subparagraph (A)(i). 

18 ‘‘(ii) The prevalence of substance use 

19 disorders. 

20 ‘‘(iii) The number of individuals who 

21 have received substance use disorder treat22 ment, including medication assisted treat23 ment, for a substance use disorder, includ24 ing treatment provided through publicly-fi25 nanced health care programs. 


sradovich on DSK3GMQ082PROD with BILLS
106 

HR 5925 RFS 

1 ‘‘(iv) The extent of the unmet need 

2 for substance use disorder treatment, in3 cluding the unmet need for medication-as4 sisted treatment. 

5 ‘‘(C) Data sufficient to show the extent of 

6 prescription drug diversion, trafficking, and 

7 misuse in the calendar year and each of the 

8 previous 3 calendar years. 

9 ‘‘(D) Any quantifiable measures the Direc10 tor determines to be appropriate to detail 

11 progress toward the achievement of the goals of 

12 the National Drug Control Strategy. 

13 ‘‘(e) ACCESS TO INFORMATION.— 

14 ‘‘(1) IN GENERAL.—Upon the request of the 

15 Director, the head of any National Drug Control 

16 Program Agency shall cooperate with and provide to 

17 the Director any statistics, studies, reports, and 

18 other information prepared or collected by the agen19 cy concerning the responsibilities of the agency 

20 under the National Drug Control Strategy that re21 late to— 

22 ‘‘(A) drug control; or 

23 ‘‘(B) the manner in which amounts made 

24 available to that agency for drug control are 

25 being used by that agency. 


sradovich on DSK3GMQ082PROD with BILLS
107 

HR 5925 RFS 

1 ‘‘(2) PROTECTION OF INTELLIGENCE INFORMA2 TION.— 

3 ‘‘(A) IN GENERAL.—The authorities con4 ferred on the Office and the Director by this 

5 chapter shall be exercised in a manner con6 sistent with provisions of the National Security 

7 Act of 1947 (50 U.S.C. 401 et seq.). The Di8 rector of National Intelligence shall prescribe 

9 such regulations as may be necessary to protect 

10 information provided pursuant to this chapter 

11 regarding intelligence sources and methods. 

12 ‘‘(B) DUTIES OF DIRECTOR.—The Director 

13 of National Intelligence and the Director of the 

14 Central Intelligence Agency shall, to the max15 imum extent practicable in accordance with 

16 subparagraph (A), render full assistance and 

17 support to the Office and the Director. 

18 ‘‘(3) REQUIRED REPORTS FROM NATIONAL

19 DRUG CONTROL PROGRAM AGENCIES.—The head of 

20 each National Drug Control Program Agency shall 

21 submit to the Director such information and reports 

22 as requested from such National Drug Control Pro23 gram Agency by the Director, which shall include 

24 from the appropriate National Drug Control Pro25 gram Agencies: 


sradovich on DSK3GMQ082PROD with BILLS
108 

HR 5925 RFS 

1 ‘‘(A) Not later than July 1 of each year, 

2 the head of a National Drug Control Program 

3 Agency designated by the Director shall submit 

4 to the Director and the appropriate congres5 sional committees an assessment of the quantity 

6 of illegal drug cultivation and manufacturing in 

7 the United States on lands owned or under the 

8 jurisdiction of their respective agencies that was 

9 seized or eradicated by their personnel during 

10 the preceding calendar year. 

11 ‘‘(B) Not later than July 1 of each year, 

12 the head of a designated National Drug Control 

13 Program Agency shall submit to the Director 

14 and the appropriate congressional committees 

15 information for the preceding year regarding— 

16 ‘‘(i) the number and type of seizures 

17 of drugs by each component of the agency 

18 seizing drugs, as well as statistical infor19 mation on the geographic areas of such 

20 seizures; and 

21 ‘‘(ii) the number of air and maritime 

22 patrol hours primarily dedicated to drug 

23 supply reduction missions undertaken by 

24 each component of the agency. 


sradovich on DSK3GMQ082PROD with BILLS
109 

HR 5925 RFS 

1 ‘‘(C) Not later than July 1 of each year, 

2 the head of a designated National Drug Control 

3 Program Agency shall submit to the Director 

4 and the appropriate congressional committees 

5 information for the preceding year regarding 

6 the number of air and maritime patrol hours 

7 primarily dedicated to drug supply reduction 

8 missions undertaken by each component of the 

9 agency. 

10 ‘‘(D) Not later than July 1 of each year, 

11 the head of a designated National Drug Control 

12 Program Agency shall submit to the Director 

13 and the appropriate congressional committees 

14 information for the preceding year regarding 

15 the number and type of— 

16 ‘‘(i) arrests for drug violations; 

17 ‘‘(ii) prosecutions by United States 

18 Attorneys for drug violations; and 

19 ‘‘(iii) seizures of drugs by each com20 ponent of the Department of Justice seiz21 ing drugs, as well as statistical information 

22 on the geographic areas of such seizures. 

23 ‘‘(f) DATA EXCHANGE STANDARDS FOR IMPROVED

24 INTEROPERABILITY.— 


sradovich on DSK3GMQ082PROD with BILLS
110 

HR 5925 RFS 

1 ‘‘(1) INTERAGENCY AND INTERGOVERNMENTAL

2 DESIGNATION AND USE OF DATA EXCHANGE STAND3 ARDS WORKING GROUP.—The Director shall estab4 lish a working group of National Drug Control Pro5 gram Agencies, State, local and Tribal government 

6 health and law enforcement agencies, and data gov7 ernance experts to develop consensus data exchange 

8 standards for necessary categories of information 

9 that allow effective electronic exchange of informa10 tion between States, between State agencies, be11 tween States and National Drug Control Program 

12 Agencies, and any other drug control relevant data 

13 exchange. 

14 ‘‘(2) DATA EXCHANGE STANDARDS MUST BE

15 NONPROPRIETARY AND INTEROPERABLE.—The data 

16 exchange standards developed under paragraph (1) 

17 shall, to the extent practicable, be nonproprietary 

18 and interoperable. 

19 ‘‘(3) OTHER REQUIREMENTS.—In developing 

20 data exchange standards under this subsection, the 

21 working group shall, to the extent practicable, incor22 porate— 

23 ‘‘(A) interoperable standards developed 

24 and maintained by an international voluntary 


sradovich on DSK3GMQ082PROD with BILLS
111 

HR 5925 RFS 

1 consensus standards body, as defined by the Of2 fice of Management and Budget; 

3 ‘‘(B) interoperable standards developed 

4 and maintained by intergovernmental partner5 ships; and 

6 ‘‘(C) interoperable standards developed 

7 and maintained by Federal entities with author8 ity over contracting and financial assistance. 

9 ‘‘(4) DATA EXCHANGE STANDARDS FOR FED10 ERAL REPORTING.— 

11 ‘‘(A) DESIGNATION.—The Director may, in 

12 consultation with the working group established 

13 under this subsection, National Drug Control 

14 Program Agencies, and State, local, and Tribal 

15 governments, designate data exchange stand16 ards to govern Federal reporting and exchange 

17 requirements for National Drug Control Pro18 grams, as appropriate. 

19 ‘‘(B) REQUIREMENTS.—The data exchange 

20 reporting standards designated under subpara21 graph (A) shall, to the extent practicable— 

22 ‘‘(i) incorporate a widely accepted, 

23 nonproprietary, searchable, machine-read24 able format; 


sradovich on DSK3GMQ082PROD with BILLS
112 

HR 5925 RFS 

1 ‘‘(ii) be consistent with and implement 

2 applicable accounting principles; 

3 ‘‘(iii) be implemented in a manner 

4 that is cost-effective and improves program 

5 efficiency and effectiveness; and 

6 ‘‘(iv) be capable of being continually 

7 upgraded as necessary. 

8 ‘‘(C) INCORPORATION OF NONPROPRI9 ETARY STANDARDS.—In designating data ex10 change standards under this paragraph, the Di11 rector shall, to the extent practicable, incor12 porate existing nonproprietary standards. 

13 ‘‘(D) RULE OF CONSTRUCTION.—Nothing 

14 in this paragraph shall be construed to require 

15 a change to existing data exchange standards 

16 for Federal reporting about a program referred 

17 to in this section, if the head of the agency re18 sponsible for administering the program finds 

19 the standards to be effective and efficient. 

20 ‘‘(5) TERMINATION.—The working group estab21 lished under paragraph (1) shall terminate not ear22 lier than 60 days after the public notification of ter23 mination by the Director. 

24 ‘‘(g) ANNUAL DATA COLLECTION AND DISSEMINA25 TION REQUIREMENTS.— 


sradovich on DSK3GMQ082PROD with BILLS
113 

HR 5925 RFS 

1 ‘‘(1) IN GENERAL.—The Director shall collect 

2 and disseminate, as appropriate, such information as 

3 the Director determines is appropriate, but not less 

4 than the information described in this subsection. To 

5 the extent practicable, the data shall be publicly 

6 available in a machine-readable format on the Drug 

7 Control Data Dashboard, be searchable by year, 

8 agency, drug, and location, and cover not less than 

9 the previous 10-year period. 

10 ‘‘(2) PREPARATION AND DISSEMINATION OF IN11 FORMATION.—The Director shall prepare and dis12 seminate the following: 

13 ‘‘(A) An assessment of current illicit drug 

14 use (including inhalants and steroids) and avail15 ability, impact of illicit drug use, and treatment 

16 availability, which assessment shall include— 

17 ‘‘(i) estimates of drug prevalence and 

18 frequency of use as measured by national, 

19 State, and local surveys of illicit drug use 

20 and by other special studies of non21 dependent and dependent illicit drug use; 

22 ‘‘(ii) illicit drug use in the workplace 

23 and the productivity lost by such use; and 

24 ‘‘(iii) illicit drug use by arrestees, pro25 bationers, and parolees. 


sradovich on DSK3GMQ082PROD with BILLS
114 

HR 5925 RFS 

1 ‘‘(B) An assessment of the reduction of il2 licit drug availability, for each drug identified 

3 under section 1005(c)(1)(A)(i), as measured 

4 by— 

5 ‘‘(i) the quantities of such drug avail6 able for consumption in the United States; 

7 ‘‘(ii) the amount of such drug enter8 ing the United States; 

9 ‘‘(iii) the number of illicit drug manu10 facturing laboratories seized and destroyed 

11 of each such drug and the number of hec12 tares cultivated and destroyed domestically 

13 and in other countries of such drug; 

14 ‘‘(iv) the number of metric tons of 

15 such drug seized; and 

16 ‘‘(v) changes in the price and purity 

17 of such drug. 

18 ‘‘(C) An assessment of the reduction of the 

19 consequences of illicit drug use and availability, 

20 which shall include— 

21 ‘‘(i) the cost of treating substance use 

22 disorder in the United States, such as the 

23 quantity of illicit drug-related services pro24 vided; 


sradovich on DSK3GMQ082PROD with BILLS
115 

HR 5925 RFS 

1 ‘‘(ii) the annual national health care 

2 cost of illicit drug use; and 

3 ‘‘(iii) the extent of illicit drug-related 

4 crime and criminal activity. 

5 ‘‘(D) A determination of the status of sub6 stance use disorder treatment in the United 

7 States, by assessing— 

8 ‘‘(i) public and private treatment utili9 zation; and 

10 ‘‘(ii) the number of illicit drug users 

11 the Director estimates meet diagnostic cri12 teria for treatment. 

13 ‘‘§ 1014. Authorization of appropriations 

14 ‘‘There are authorized to be appropriated to carry out 

15 this chapter, except as otherwise specified, to remain avail16 able until expended, $18.4 million for each of fiscal years 

17 2019 through 2023. 

18 ‘‘SUBCHAPTER II—DRUG-FREE COMMUNITIES 

19 SUPPORT PROGRAM 

20 ‘‘§ 1021. Establishment of drug-free communities sup21 port program 

22 ‘‘(a) ESTABLISHMENT.—The Director shall establish 

23 a program to support communities in the development and 

24 implementation of comprehensive, long-term plans and 


sradovich on DSK3GMQ082PROD with BILLS
116 

HR 5925 RFS 

1 programs to prevent and treat substance use and misuse 

2 among youth. 

3 ‘‘(b) PROGRAM.—In carrying out the Program, the 

4 Director shall— 

5 ‘‘(1) make and track grants to grant recipients; 

6 ‘‘(2) provide for technical assistance and train7 ing, data collection, and dissemination of informa8 tion on state-of-the-art practices that the Director 

9 determines to be effective in reducing substance use; 

10 and 

11 ‘‘(3) provide for the general administration of 

12 the Program. 

13 ‘‘(c) ADMINISTRATION.—The Director shall appoint 

14 an Administrator to carry out the Program. 

15 ‘‘(d) CONTRACTING.—The Director may employ any 

16 necessary staff and may enter into contracts or agree17 ments with National Drug Control Program Agencies, in18 cluding interagency agreements, to delegate authority for 

19 the execution of grants and for such other activities nec20 essary to carry out this chapter. 

21 ‘‘§ 1022. Program authorization 

22 ‘‘(a) GRANT ELIGIBILITY.—To be eligible to receive 

23 an initial grant or a renewal grant under this subchapter, 

24 a coalition shall meet each of the following criteria: 


sradovich on DSK3GMQ082PROD with BILLS
117 

HR 5925 RFS 

1 ‘‘(1) APPLICATION.—The coalition shall submit 

2 an application to the Administrator in accordance 

3 with section 1023(a)(2). 

4 ‘‘(2) MAJOR SECTOR INVOLVEMENT.— 

5 ‘‘(A) IN GENERAL.—The coalition shall 

6 consist of one or more representatives of each 

7 of the following categories: 

8 ‘‘(i) Youth. 

9 ‘‘(ii) Parents. 

10 ‘‘(iii) Businesses. 

11 ‘‘(iv) The media. 

12 ‘‘(v) Schools. 

13 ‘‘(vi) Organizations serving youth. 

14 ‘‘(vii) Law enforcement. 

15 ‘‘(viii) Religious or fraternal organiza16 tions. 

17 ‘‘(ix) Civic and volunteer groups. 

18 ‘‘(x) Health care professionals. 

19 ‘‘(xi) State, local, or Tribal govern20 mental agencies with expertise in the field 

21 of substance use prevention or substance 

22 use disorders (including, if applicable, the 

23 State authority with primary authority for 

24 substance use and misuse). 


sradovich on DSK3GMQ082PROD with BILLS
118 

HR 5925 RFS 

1 ‘‘(xii) Other organizations involved in 

2 reducing the prevalence of substance use 

3 and misuse or substance use disorders. 

4 ‘‘(B) ELECTED OFFICIALS.—If feasible, in 

5 addition to representatives from the categories 

6 listed in subparagraph (A), the coalition shall 

7 have an elected official (or a representative of 

8 an elected official) from— 

9 ‘‘(i) the Federal Government; and 

10 ‘‘(ii) the government of the appro11 priate State and political subdivision there12 of or the governing body or an Indian tribe 

13 (as that term is defined in section 4(e) of 

14 the Indian Self-Determination Act (25 

15 U.S.C. 5304)). 

16 ‘‘(C) REPRESENTATION.—An individual 

17 who is a member of the coalition may serve on 

18 the coalition as a representative of not more 

19 than one category listed under subparagraph 

20 (A). 

21 ‘‘(3) COMMITMENT.—The coalition shall dem22 onstrate, to the satisfaction of the Administrator— 

23 ‘‘(A) that the representatives of the coali24 tion have worked together on substance use and 

25 misuse reduction initiatives, which, at a minVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00118 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
119 

HR 5925 RFS 

1 imum, includes initiatives that target drugs de2 scribed in section 1027(6)(A), for a period of 

3 not less than 6 months, acting through entities 

4 such as task forces, subcommittees, or commu5 nity boards; and 

6 ‘‘(B) substantial participation from volun7 teer leaders in the community involved (espe8 cially in cooperation with individuals involved 

9 with youth such as parents, teachers, coaches, 

10 youth workers, and members of the clergy). 

11 ‘‘(4) MISSION AND STRATEGIES.—The coalition 

12 shall, with respect to the community involved— 

13 ‘‘(A) have as its principal mission the re14 duction of illegal drug use, which, at a min15 imum, includes the use of illegal drugs de16 scribed in section 1027(6)(A), in a comprehen17 sive and long-term manner, with a primary 

18 focus on youth in the community; 

19 ‘‘(B) describe and document the nature 

20 and extent of the substance use and misuse 

21 problem, which, at a minimum, includes the use 

22 and misuse of drugs described in section 

23 1027(6)(A), in the community; 

24 ‘‘(C)(i) provide a description of substance 

25 use and misuse prevention and treatment proVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00119 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
120 

HR 5925 RFS 

1 grams and activities, which, at a minimum, in2 cludes programs and activities relating to the 

3 use and misuse of drugs described in section 

4 1027(6)(A), in existence at the time of the 

5 grant application; and 

6 ‘‘(ii) identify substance use and misuse 

7 programs and service gaps, which, at a min8 imum, includes programs and gaps relating to 

9 the use and misuse of drugs described in sec10 tion 1027(6)(A), in the community; 

11 ‘‘(D) develop a strategic plan to reduce 

12 substance use and misuse among youth, which, 

13 at a minimum, includes the use and misuse of 

14 drugs described in section 1027(6)(A), in a 

15 comprehensive and long-term fashion; and 

16 ‘‘(E) work to develop a consensus regard17 ing the priorities of the community to combat 

18 substance use and misuse among youth, which, 

19 at a minimum, includes the use and misuse of 

20 drugs described in section 1027(6)(A). 

21 ‘‘(5) SUSTAINABILITY.—The coalition shall 

22 demonstrate that the coalition is an ongoing concern 

23 by demonstrating that the coalition— 

24 ‘‘(A) is— 

25 ‘‘(i)(I) a nonprofit organization; or 


sradovich on DSK3GMQ082PROD with BILLS
121 

HR 5925 RFS 

1 ‘‘(II) an entity that the Administrator 

2 determines to be appropriate; or 

3 ‘‘(ii) part of, or is associated with, an 

4 established legal entity; 

5 ‘‘(B) receives financial support (including, 

6 in the discretion of the Administrator, in-kind 

7 contributions) from non-Federal sources; and 

8 ‘‘(C) has a strategy to solicit substantial fi9 nancial support from non-Federal sources to en10 sure that the coalition and the programs oper11 ated by the coalition are self-sustaining. 

12 ‘‘(6) ACCOUNTABILITY.—The coalition shall— 

13 ‘‘(A) establish a system to measure and re14 port outcomes— 

15 ‘‘(i) consistent with common indica16 tors and evaluation protocols established 

17 by the Administrator; and 

18 ‘‘(ii) approved by the Administrator; 

19 ‘‘(B) conduct— 

20 ‘‘(i) for an initial grant under this 

21 subchapter, an initial benchmark survey of 

22 drug use among youth (or use local sur23 veys or performance measures available or 

24 accessible in the community at the time of 

25 the grant application); and 


sradovich on DSK3GMQ082PROD with BILLS
122 

HR 5925 RFS 

1 ‘‘(ii) biennial surveys (or incorporate 

2 local surveys in existence at the time of the 

3 evaluation) to measure the progress and 

4 effectiveness of the coalition; and 

5 ‘‘(C) provide assurances that the entity 

6 conducting an evaluation under this paragraph, 

7 or from which the coalition receives informa8 tion, has experience— 

9 ‘‘(i) in gathering data related to sub10 stance use and misuse among youth; or 

11 ‘‘(ii) in evaluating the effectiveness of 

12 community anti-drug coalitions. 

13 ‘‘(7) ADDITIONAL CRITERIA.—The Director 

14 shall not impose any eligibility criteria on new appli15 cants or renewal grantees not provided in this chap16 ter. 

17 ‘‘(b) GRANT AMOUNTS.— 

18 ‘‘(1) IN GENERAL.— 

19 ‘‘(A) GRANTS.— 

20 ‘‘(i) IN GENERAL.—Subject to clause 

21 (iv), for a fiscal year, the Administrator 

22 may grant to an eligible coalition under 

23 this paragraph, an amount not to exceed 

24 the amount of non-Federal funds raised by 


sradovich on DSK3GMQ082PROD with BILLS
123 

HR 5925 RFS 

1 the coalition, including in-kind contribu2 tions, for that fiscal year. 

3 ‘‘(ii) SUSPENSION OF GRANTS.—If 

4 such grant recipient fails to continue to 

5 meet the criteria specified in subsection 

6 (a), the Administrator may suspend the 

7 grant, after providing written notice to the 

8 grant recipient and an opportunity to ap9 peal. 

10 ‘‘(iii) RENEWAL GRANTS.—Subject to 

11 clause (iv), the Administrator may award a 

12 renewal grant to a grant recipient under 

13 this subparagraph for each fiscal year fol14 lowing the fiscal year for which an initial 

15 grant is awarded, in an amount not to ex16 ceed the amount of non-Federal funds 

17 raised by the coalition, including in-kind 

18 contributions, for that fiscal year, during 

19 the 4-year period following the period of 

20 the initial grant. 

21 ‘‘(iv) LIMITATION.—The amount of a 

22 grant award under this subparagraph may 

23 not exceed $125,000 for a fiscal year. 

24 ‘‘(B) COALITION AWARDS.— 


sradovich on DSK3GMQ082PROD with BILLS
124 

HR 5925 RFS 

1 ‘‘(i) IN GENERAL.—Except as pro2 vided in clause (ii), the Administrator may, 

3 with respect to a community, make a grant 

4 to one eligible coalition that represents 

5 that community. 

6 ‘‘(ii) EXCEPTION.—The Administrator 

7 may make a grant to more than one eligi8 ble coalition that represents a community 

9 if— 

10 ‘‘(I) the eligible coalitions dem11 onstrate that the coalitions are col12 laborating with one another; and 

13 ‘‘(II) each of the coalitions has 

14 independently met the requirements 

15 set forth in subsection (a). 

16 ‘‘(2) RURAL COALITION GRANTS.— 

17 ‘‘(A) IN GENERAL.— 

18 ‘‘(i) IN GENERAL.—In addition to 

19 awarding grants under paragraph (1), to 

20 stimulate the development of coalitions in 

21 sparsely populated and rural areas, the 

22 Administrator may award a grant in ac23 cordance with this section to a coalition 

24 that represents a county with a population 

25 that does not exceed 30,000 individuals. In 


sradovich on DSK3GMQ082PROD with BILLS
125 

HR 5925 RFS 

1 awarding a grant under this paragraph, 

2 the Administrator may waive any require3 ment under subsection (a) if the Adminis4 trator considers that waiver to be appro5 priate. 

6 ‘‘(ii) MATCHING REQUIREMENT.— 

7 Subject to subparagraph (C), for a fiscal 

8 year, the Administrator may grant to an 

9 eligible coalition under this paragraph, an 

10 amount not to exceed the amount of non11 Federal funds raised by the coalition, in12 cluding in-kind contributions, for that fis13 cal year. 

14 ‘‘(iii) SUSPENSION OF GRANTS.—If 

15 such grant recipient fails to continue to 

16 meet any criteria specified in subsection 

17 (a) that has not been waived by the Ad18 ministrator pursuant to clause (i), the Ad19 ministrator may suspend the grant, after 

20 providing written notice to the grant re21 cipient and an opportunity to appeal. 

22 ‘‘(B) RENEWAL GRANTS.—The Adminis23 trator may award a renewal grant to an eligible 

24 coalition that is a grant recipient under this 

25 paragraph for each fiscal year following the fisVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00125 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
126 

HR 5925 RFS 

1 cal year for which an initial grant is awarded, 

2 in an amount not to exceed the amount of non3 Federal funds raised by the coalition, including 

4 in-kind contributions, during the 4-year period 

5 following the period of the initial grant. 

6 ‘‘(C) LIMITATIONS.— 

7 ‘‘(i) AMOUNT.—The amount of a 

8 grant award under this paragraph shall 

9 not exceed $125,000 for a fiscal year. 

10 ‘‘(ii) AWARDS.—With respect to a 

11 county referred to in subparagraph (A), 

12 the Administrator may award a grant 

13 under this section to not more than one el14 igible coalition that represents the county. 

15 ‘‘(3) ADDITIONAL GRANTS.— 

16 ‘‘(A) IN GENERAL.—Subject to subpara17 graph (F), the Administrator may award an ad18 ditional grant under this paragraph to an eligi19 ble coalition awarded a grant under paragraph 

20 (1) or (2) for any first fiscal year after the end 

21 of the 4-year period following the period of the 

22 initial grant under paragraph (1) or (2), as the 

23 case may be. 

24 ‘‘(B) SCOPE OF GRANTS.—A coalition 

25 awarded a grant under paragraph (1) or (2), 


sradovich on DSK3GMQ082PROD with BILLS
127 

HR 5925 RFS 

1 including a renewal grant under such para2 graph, may not be awarded another grant 

3 under such paragraph, and is eligible for an ad4 ditional grant under this section only under this 

5 paragraph. 

6 ‘‘(C) NO PRIORITY FOR APPLICATIONS.— 

7 The Administrator may not afford a higher pri8 ority in the award of an additional grant under 

9 this paragraph than the Administrator would 

10 afford the applicant for the grant if the appli11 cant were submitting an application for an ini12 tial grant under paragraph (1) or (2) rather 

13 than an application for a grant under this para14 graph. 

15 ‘‘(D) RENEWAL GRANTS.—Subject to sub16 paragraph (F), the Administrator may award a 

17 renewal grant to a grant recipient under this 

18 paragraph for each of the fiscal years of the 4- 

19 fiscal-year period following the fiscal year for 

20 which the initial additional grant under sub21 paragraph (A) is awarded in an amount not to 

22 exceed amounts as follows: 

23 ‘‘(i) For the first and second fiscal 

24 years of that 4-fiscal-year period, the 

25 amount of the non-Federal funds, includVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00127 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
128 

HR 5925 RFS 

1 ing in-kind contributions, raised by the co2 alition for the applicable fiscal year is not 

3 less than 125 percent of the amount 

4 awarded. 

5 ‘‘(ii) For the third and fourth fiscal 

6 years of that 4-fiscal-year period, the 

7 amount of the non-Federal funds, includ8 ing in-kind contributions, raised by the co9 alition for the applicable fiscal year is not 

10 less than 150 percent of the amount 

11 awarded. 

12 ‘‘(E) SUSPENSION.—If a grant recipient 

13 under this paragraph fails to continue to meet 

14 the criteria specified in subsection (a), the Ad15 ministrator may suspend the grant, after pro16 viding written notice to the grant recipient and 

17 an opportunity to appeal. 

18 ‘‘(F) LIMITATION.—The amount of a grant 

19 award under this paragraph may not exceed 

20 $125,000 for a fiscal year. 

21 ‘‘(4) PROCESS FOR SUSPENSION.—A grantee 

22 shall not be suspended or terminated under para23 graph (1)(A)(ii), (2)(A)(iii), or (3)(E) unless that 

24 grantee is afforded a fair, timely, and independent 

25 appeal prior to such suspension or termination. 


sradovich on DSK3GMQ082PROD with BILLS
129 

HR 5925 RFS 

1 ‘‘(c) TREATMENT OF FUNDS FOR COALITIONS REP2 RESENTING CERTAIN ORGANIZATIONS.—Funds appro3 priated for the substance use and misuse activities of a 

4 coalition that includes a representative of the Bureau of 

5 Indian Affairs, the Indian Health Service, or a Tribal gov6 ernment agency with expertise in the field of substance 

7 use prevention may be counted as non-Federal funds 

8 raised by the coalition for purposes of this section. 

9 ‘‘(d) PRIORITY IN AWARDING GRANTS.—In awarding 

10 grants under subsection (b)(1)(A)(i), priority shall be 

11 given to a coalition serving economically disadvantaged 

12 areas. 

13 ‘‘§ 1023. Information collection and dissemination 

14 with respect to grant recipients 

15 ‘‘(a) COALITION INFORMATION.— 

16 ‘‘(1) GENERAL AUDITING AUTHORITY.—For the 

17 purpose of audit and examination, the Adminis18 trator— 

19 ‘‘(A) shall have access to any books, docu20 ments, papers, and records that are pertinent to 

21 any grant or grant renewal request under this 

22 subchapter; and 

23 ‘‘(B) may periodically request information 

24 from a grant recipient to ensure that the grant 


sradovich on DSK3GMQ082PROD with BILLS
130 

HR 5925 RFS 

1 recipient meets the applicable criteria under 

2 section 1022(a). 

3 ‘‘(2) APPLICATION PROCESS.—The Adminis4 trator shall issue a request for proposal regarding, 

5 with respect to the grants awarded under section 

6 1022, the application process, grant renewal, and 

7 suspension or withholding of renewal grants. Each 

8 application under this paragraph shall be in writing 

9 and shall be subject to review by the Administrator. 

10 ‘‘(3) REPORTING.—The Administrator shall, to 

11 the maximum extent practicable and in a manner 

12 consistent with applicable law, minimize reporting 

13 requirements by a grant recipient and expedite any 

14 application for a renewal grant made under this sub15 chapter. 

16 ‘‘(b) DATA COLLECTION AND DISSEMINATION.— 

17 ‘‘(1) IN GENERAL.—The Administrator may 

18 collect data from— 

19 ‘‘(A) national substance use and misuse or20 ganizations that work with eligible coalitions, 

21 community anti-drug coalitions, departments or 

22 agencies of the Federal Government, or State 

23 or local governments and the governing bodies 

24 of Indian Tribes; and 


sradovich on DSK3GMQ082PROD with BILLS
131 

HR 5925 RFS 

1 ‘‘(B) any other entity or organization that 

2 carries out activities that relate to the purposes 

3 of the Program. 

4 ‘‘(2) ACTIVITIES OF ADMINISTRATOR.—The Ad5 ministrator may— 

6 ‘‘(A) evaluate the utility of specific initia7 tives relating to the purposes of the Program; 

8 ‘‘(B) conduct an evaluation of the Pro9 gram; and 

10 ‘‘(C) disseminate information described in 

11 this subsection to— 

12 ‘‘(i) eligible coalitions and other sub13 stance use prevention organizations; and 

14 ‘‘(ii) the general public. 

15 ‘‘(3) CONSULTATION.—The Administrator shall 

16 carry out activities under this subsection in consulta17 tion with the National Community Antidrug Coali18 tion Institute. 

19 ‘‘(4) LIMITATION ON USE OF CERTAIN FUNDS

20 FOR EVALUATION OF PROGRAM.—Amounts for ac21 tivities under paragraph (2)(B) may not be derived 

22 from amounts under section 1028(a) except for 

23 amounts that are available under section 1028(b) for 

24 administrative costs. 


sradovich on DSK3GMQ082PROD with BILLS
132 

HR 5925 RFS 

1 ‘‘§ 1024. Technical assistance and training 

2 ‘‘(a) IN GENERAL.— 

3 ‘‘(1) TECHNICAL ASSISTANCE AND AGREE4 MENTS.—With respect to any grant recipient or 

5 other organization, the Administrator may— 

6 ‘‘(A) offer technical assistance and train7 ing; and 

8 ‘‘(B) enter into contracts and cooperative 

9 agreements. 

10 ‘‘(2) COORDINATION OF PROGRAMS.—The Ad11 ministrator may facilitate the coordination of pro12 grams between a grant recipient and other organiza13 tions and entities. 

14 ‘‘(b) TRAINING.—The Administrator may provide 

15 training to any representative designated by a grant re16 cipient in— 

17 ‘‘(1) coalition building; 

18 ‘‘(2) task force development; 

19 ‘‘(3) mediation and facilitation, direct service, 

20 assessment and evaluation; or 

21 ‘‘(4) any other activity related to the purposes 

22 of the Program. 

23 ‘‘§ 1025. Supplemental grants for coalition mentoring 

24 activities 

25 ‘‘(a) AUTHORITY TO MAKE GRANTS.—As part of the 

26 Program, the Director may award an initial grant under 


sradovich on DSK3GMQ082PROD with BILLS
133 

HR 5925 RFS 

1 this subsection, and renewal grants under subsection (f), 

2 to any coalition awarded a grant under section 1022 that 

3 meets the criteria specified in subsection (d) in order to 

4 fund coalition mentoring activities by such coalition in 

5 support of the program. 

6 ‘‘(b) TREATMENT WITH OTHER GRANTS.— 

7 ‘‘(1) SUPPLEMENT.—A grant awarded to a coa8 lition under this section is in addition to any grant 

9 awarded to the coalition under section 1022. 

10 ‘‘(2) REQUIREMENT FOR BASIC GRANT.—A coa11 lition may not be awarded a grant under this section 

12 for a fiscal year unless the coalition was awarded a 

13 grant or renewal grant under section 1022(b) for 

14 that fiscal year. 

15 ‘‘(c) APPLICATION.—A coalition seeking a grant 

16 under this section shall submit to the Administrator an 

17 application for the grant in such form and manner as the 

18 Administrator may require. 

19 ‘‘(d) CRITERIA.—A coalition meets the criteria speci20 fied in this subsection if the coalition— 

21 ‘‘(1) has been in existence for at least 5 years; 

22 ‘‘(2) has achieved, by or through its own ef23 forts, measurable results in the prevention and treat24 ment of substance use and misuse among youth; 


sradovich on DSK3GMQ082PROD with BILLS
134 

HR 5925 RFS 

1 ‘‘(3) has staff or members willing to serve as 

2 mentors for persons seeking to start or expand the 

3 activities of other coalitions in the prevention and 

4 treatment of substance use and misuse; 

5 ‘‘(4) has demonstrable support from some mem6 bers of the community in which the coalition men7 toring activities to be supported by the grant under 

8 this section are to be carried out; and 

9 ‘‘(5) submits to the Administrator a detailed 

10 plan for the coalition mentoring activities to be sup11 ported by the grant under this section. 

12 ‘‘(e) USE OF GRANT FUNDS.—A coalition awarded 

13 a grant under this section shall use the grant amount for 

14 mentoring activities to support and encourage the develop15 ment of new, self-supporting community coalitions that 

16 are focused on the prevention and treatment of substance 

17 use and misuse in such new coalitions’ communities. The 

18 mentoring coalition shall encourage such development in 

19 accordance with the plan submitted by the mentoring coa20 lition under subsection (d)(5). 

21 ‘‘(f) RENEWAL GRANTS.—The Administrator may 

22 make a renewal grant to any coalition awarded a grant 

23 under subsection (a), or a previous renewal grant under 

24 this subsection, if the coalition, at the time of application 

25 for such renewal grant— 


sradovich on DSK3GMQ082PROD with BILLS
135 

HR 5925 RFS 

1 ‘‘(1) continues to meet the criteria specified in 

2 subsection (d); and 

3 ‘‘(2) has made demonstrable progress in the de4 velopment of one or more new, self-supporting com5 munity coalitions that are focused on the prevention 

6 and treatment of substance use and misuse. 

7 ‘‘(g) GRANT AMOUNTS.— 

8 ‘‘(1) IN GENERAL.—Subject to paragraphs (2) 

9 and (3), the total amount of grants awarded to a co10 alition under this section for a fiscal year may not 

11 exceed the amount of non-Federal funds raised by 

12 the coalition, including in-kind contributions, for 

13 that fiscal year. Funds appropriated for the sub14 stance use and misuse activities of a coalition that 

15 includes a representative of the Bureau of Indian 

16 Affairs, the Indian Health Service, or a Tribal gov17 ernment agency with expertise in the field of sub18 stance use prevention may be counted as non-Fed19 eral funds raised by the coalition. 

20 ‘‘(2) INITIAL GRANTS.—The amount of the ini21 tial grant awarded to a coalition under subsection 

22 (a) may not exceed $75,000. 

23 ‘‘(3) RENEWAL GRANTS.—The total amount of 

24 renewal grants awarded to a coalition under subVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00135 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
136 

HR 5925 RFS 

1 section (f) for any fiscal year may not exceed 

2 $75,000. 

3 ‘‘(h) FISCAL YEAR LIMITATION ON AMOUNT AVAIL4 ABLE FOR GRANTS.—The total amount available for 

5 grants under this section, including renewal grants under 

6 subsection (f), in any fiscal year may not exceed the 

7 amount equal to 5 percent of the amount authorized to 

8 be appropriated by section 1028 for that fiscal year. 

9 ‘‘(i) PRIORITY IN AWARDING INITIAL GRANTS.—In 

10 awarding initial grants under this section, priority shall 

11 be given to a coalition that expressly proposes to provide 

12 mentorship to a coalition or aspiring coalition serving eco13 nomically disadvantaged areas. 

14 ‘‘§ 1026. Authorization for National Community Anti15 drug Coalition Institute 

16 ‘‘(a) IN GENERAL.—The Director shall, using 

17 amounts authorized to be appropriated by subsection (d), 

18 make a competitive grant to provide for the continuation 

19 of the National Community Anti-drug Coalition Institute. 

20 ‘‘(b) ELIGIBLE ORGANIZATIONS.—An organization 

21 eligible for the grant under subsection (a) is any national 

22 nonprofit organization that represents, provides technical 

23 assistance and training to, and has special expertise and 

24 broad, national-level experience in community antidrug 

25 coalitions under this subchapter. 


sradovich on DSK3GMQ082PROD with BILLS
137 

HR 5925 RFS 

1 ‘‘(c) USE OF GRANT AMOUNT.—The organization 

2 that receives the grant under subsection (a) shall continue 

3 a National Community Anti-Drug Coalition Institute to— 

4 ‘‘(1) provide education, training, and technical 

5 assistance for coalition leaders and community 

6 teams, with emphasis on the development of coali7 tions serving economically disadvantaged areas; 

8 ‘‘(2) develop and disseminate evaluation tools, 

9 mechanisms, and measures to better assess and doc10 ument coalition performance measures and out11 comes; and 

12 ‘‘(3) bridge the gap between research and prac13 tice by translating knowledge from research into 

14 practical information. 

15 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—The 

16 Director shall, using amounts authorized to be appro17 priated by section 1028, make a grant of $2 million under 

18 subsection (a), for each of the fiscal years 2019 through 

19 2023. 

20 ‘‘§ 1027. Definitions 

21 ‘‘In this subchapter: 

22 ‘‘(1) ADMINISTRATOR.—The term ‘Adminis23 trator’ means the Administrator appointed by the 

24 Director under section 1021(c). 


sradovich on DSK3GMQ082PROD with BILLS
138 

HR 5925 RFS 

1 ‘‘(2) COMMUNITY.—The term ‘community’ shall 

2 have the meaning provided that term by the Admin3 istrator. 

4 ‘‘(3) ELIGIBLE COALITION.—The term ‘eligible 

5 coalition’ means a coalition that meets the applicable 

6 criteria under section 1022(a). 

7 ‘‘(4) GRANT RECIPIENT.—The term ‘grant re8 cipient’ means the recipient of a grant award under 

9 section 1022. 

10 ‘‘(5) PROGRAM.—The term ‘Program’ means 

11 the program established under section 1021(a). 

12 ‘‘(6) SUBSTANCE USE AND MISUSE.—The term 

13 ‘substance use and misuse’ means— 

14 ‘‘(A) the illegal use or misuse of drugs, in15 cluding substances for which a listing is in ef16 fect under any of schedules I through V under 

17 section 202 of the Controlled Substances Act 

18 (21 U.S.C. 812); 

19 ‘‘(B) the misuse of inhalants or over the 

20 counter drugs; or 

21 ‘‘(C) the use of alcohol, tobacco, or other 

22 related product as such use is prohibited by 

23 State or local law. 

24 ‘‘(7) YOUTH.—The term ‘youth’ shall have the 

25 meaning provided that term by the Administrator. 


sradovich on DSK3GMQ082PROD with BILLS
139 

HR 5925 RFS 

1 ‘‘§ 1028. Drug–free communities reauthorization 

2 ‘‘(a) AUTHORIZATION OF APPROPRIATIONS.—There 

3 are authorized to be appropriated to the Office to carry 

4 out this subchapter $99 million for each of the fiscal years 

5 2019 through 2023. 

6 ‘‘(b) ADMINISTRATIVE COSTS.—Not more than 8 

7 percent of the funds appropriated for this subchapter may 

8 be used by the Office or, in the discretion of the Director, 

9 an agency delegated to carry out the program under sec10 tion 1021(d) to pay for administrative costs associated 

11 with carrying out the program.’’. 

12 (d) TECHNICAL AND CONFORMING AMENDMENT.— 

13 The table of chapters for subtitle I of title 31, United 

14 States Code, is amended by adding at the end the fol15 lowing new item: 

‘‘10. Office of National Drug Control ...................................................... 1001’’. 

16 SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PRO17 GRAM. 

18 (a) ESTABLISHMENT.— 

19 (1) IN GENERAL.—There is established in the 

20 Office a program to be known as the High Intensity 

21 Drug Trafficking Areas Program (in this section re22 ferred to as the ‘‘Program’’). 

23 (2) PURPOSE.—The purpose of the Program is 

24 to reduce drug trafficking and drug production in 

25 the United States by— 


sradovich on DSK3GMQ082PROD with BILLS
140 

HR 5925 RFS 

1 (A) facilitating cooperation among Federal, 

2 State, local, and Tribal law enforcement agen3 cies to share information and implement coordi4 nated enforcement activities; 

5 (B) enhancing law enforcement intelligence 

6 sharing among Federal, State, local, and Tribal 

7 law enforcement agencies; 

8 (C) providing reliable law enforcement in9 telligence to law enforcement agencies needed to 

10 design effective enforcement strategies and op11 erations; and 

12 (D) supporting coordinated law enforce13 ment strategies which maximize use of available 

14 resources to reduce the supply of illegal drugs 

15 in designated areas and in the United States as 

16 a whole. 

17 (b) DESIGNATION.— 

18 (1) IN GENERAL.—The Director, in consulta19 tion with the Attorney General, the Secretary of the 

20 Treasury, the Secretary of Homeland Security, the 

21 head of each National Drug Control Program Agen22 cy, and the Governor of each applicable State, may 

23 designate any specified area of the United States as 

24 a high intensity drug trafficking area. 


sradovich on DSK3GMQ082PROD with BILLS
141 

HR 5925 RFS 

1 (2) ACTIVITIES.—After making a designation 

2 under paragraph (1) and in order to provide Federal 

3 assistance to the area so designated, the Director 

4 may— 

5 (A) obligate such sums as are appropriated 

6 for the Program; 

7 (B) direct the temporary reassignment of 

8 Federal personnel to such area, subject to the 

9 approval of the head of the agency that employs 

10 such personnel; 

11 (C) take any other action authorized under 

12 this section or chapter 10 of title 31, United 

13 States Code, as added by section 2(c), to pro14 vide increased Federal assistance to those 

15 areas; and 

16 (D) coordinate activities under this section 

17 (specifically administrative, recordkeeping, and 

18 funds management activities) with State, local, 

19 and Tribal officials. 

20 (c) PETITIONS FOR DESIGNATION.—The Director 

21 shall establish and maintain regulations under which a co22 alition of interested law enforcement agencies from an 

23 area may petition for designation as a high intensity drug 

24 trafficking area (in this section referred to as the 

25 ‘‘HIDTA’’). Such regulations shall provide for a regular 


sradovich on DSK3GMQ082PROD with BILLS
142 

HR 5925 RFS 

1 review by the Director of the petition, including a rec2 ommendation regarding the merit of the petition to the 

3 Director by a panel of qualified, independent experts. 

4 (d) FACTORS FOR CONSIDERATION.—In considering 

5 whether to designate an area under this section as a high 

6 intensity drug trafficking area, the Director shall consider, 

7 in addition to such other criteria as the Director considers 

8 to be appropriate, the extent to which— 

9 (1) the area is a significant center of illegal 

10 drug production, manufacturing, importation, or dis11 tribution; 

12 (2) State, local, and Tribal law enforcement 

13 agencies have committed resources to respond to the 

14 drug trafficking problem in the area, thereby indi15 cating a determination to respond aggressively to the 

16 problem; 

17 (3) drug-related activities in the area are hav18 ing a significant harmful impact in the area, and in 

19 other areas of the country; and 

20 (4) a significant increase in allocation of Fed21 eral resources is necessary to respond adequately to 

22 drug-related activities in the area. 

23 (e) ORGANIZATION OF HIGH INTENSITY DRUG TRAF24 FICKING AREAS.— 


sradovich on DSK3GMQ082PROD with BILLS
143 

HR 5925 RFS 

1 (1) EXECUTIVE BOARD AND OFFICERS.—To be 

2 eligible for funds appropriated under this section, 

3 each high intensity drug trafficking area shall be 

4 governed by an Executive Board. The Executive 

5 Board shall designate a chairman, vice chairman, 

6 and any other officers to the Executive Board that 

7 it determines are necessary. 

8 (2) RESPONSIBILITIES.—The Executive Board 

9 of a high intensity drug trafficking area shall be re10 sponsible for— 

11 (A) providing direction and oversight in es12 tablishing and achieving the goals of the high 

13 intensity drug trafficking area; 

14 (B) managing the funds of the high inten15 sity drug trafficking area; 

16 (C) reviewing and approving all funding 

17 proposals consistent with the overall objective of 

18 the high intensity drug trafficking area; and 

19 (D) reviewing and approving all reports to 

20 the Director on the activities of the high inten21 sity drug trafficking area. 

22 (3) BOARD REPRESENTATION.—None of the 

23 funds appropriated under this section may be ex24 pended for any high intensity drug trafficking area, 

25 or for a partnership or region of a high intensity 


sradovich on DSK3GMQ082PROD with BILLS
144 

HR 5925 RFS 

1 drug trafficking area, if the Executive Board for 

2 such area, region, or partnership, does not apportion 

3 an equal number of votes between representatives of 

4 participating agencies and representatives of partici5 pating State, local, and Tribal agencies. Where it is 

6 impractical for an equal number of representatives 

7 of agencies and State, local, and Tribal agencies to 

8 attend a meeting of an Executive Board in person, 

9 the Executive Board may use a system of proxy 

10 votes or weighted votes to achieve the voting balance 

11 required by this paragraph. 

12 (4) NO AGENCY RELATIONSHIP.—The eligibility 

13 requirements of this section are intended to ensure 

14 the responsible use of Federal funds. Nothing in this 

15 section is intended to create an agency relationship 

16 between individual high intensity drug trafficking 

17 areas and the Federal Government. 

18 (f) USE OF FUNDS.—The Director shall ensure that 

19 not more than 5 percent of Federal funds appropriated 

20 for the Program are expended for substance use disorder 

21 treatment programs and not more than 5 percent of the 

22 Federal funds appropriated for the Program are expended 

23 for drug prevention programs. 

24 (g) COUNTERTERRORISM ACTIVITIES.— 


sradovich on DSK3GMQ082PROD with BILLS
145 

HR 5925 RFS 

1 (1) ASSISTANCE AUTHORIZED.—The Director 

2 may authorize use of resources available for the Pro3 gram to assist Federal, State, local, and Tribal law 

4 enforcement agencies in investigations and activities 

5 related to terrorism and prevention of terrorism, es6 pecially but not exclusively with respect to such in7 vestigations and activities that are also related to 

8 drug trafficking. 

9 (2) LIMITATION.—The Director shall ensure— 

10 (A) that assistance provided under para11 graph (1) remains incidental to the purpose of 

12 the Program to reduce drug availability and 

13 carry out drug-related law enforcement activi14 ties; and 

15 (B) that significant resources of the Pro16 gram are not redirected to activities exclusively 

17 related to terrorism, except on a temporary 

18 basis under extraordinary circumstances, as de19 termined by the Director. 

20 (h) ROLE OF DRUG ENFORCEMENT ADMINISTRA21 TION.—The Director, in consultation with the Attorney 

22 General, shall ensure that a representative of the Drug 

23 Enforcement Administration is included in the Intelligence 

24 Support Center for each high intensity drug trafficking 

25 area. 


sradovich on DSK3GMQ082PROD with BILLS
146 

HR 5925 RFS 

1 (i) EMERGING THREAT RESPONSE FUND.— 

2 (1) IN GENERAL.—Subject to the availability of 

3 appropriations, the Director may expend up to 10 

4 percent of the amounts appropriated under this sec5 tion on a discretionary basis, in accordance with the 

6 criteria established under paragraph (2)— 

7 (A) to respond to any emerging drug traf8 ficking threat in an existing high intensity drug 

9 trafficking area; 

10 (B) to establish a new high intensity drug 

11 trafficking area; or 

12 (C) to expand an existing high intensity 

13 drug trafficking area. 

14 (2) CONSIDERATION OF IMPACT.—In allocating 

15 funds under this subsection, the Director shall con16 sider— 

17 (A) the impact of activities funded on re18 ducing overall drug traffic in the United States, 

19 or minimizing the probability that an emerging 

20 drug trafficking threat will spread to other 

21 areas of the United States; and 

22 (B) such other criteria as the Director con23 siders appropriate. 

24 (j) ANNUAL HIDTA PROGRAM BUDGET SUBMIS25 SIONS.—As part of the documentation that supports the 


sradovich on DSK3GMQ082PROD with BILLS
147 

HR 5925 RFS 

1 President’s annual budget request for the Office, the Di2 rector shall submit to Congress a budget justification that 

3 includes— 

4 (1) the amount proposed for each HIDTA, con5 ditional upon a review by the Office of the request 

6 submitted by such HIDTA and the performance of 

7 such HIDTA, with supporting narrative descriptions 

8 and rationale for each request; 

9 (2) a detailed justification that explains— 

10 (A) the reasons for the proposed funding 

11 level and how such funding level was deter12 mined based on a current assessment of the 

13 drug trafficking threat in each high intensity 

14 drug trafficking area; 

15 (B) how such funding will ensure that the 

16 goals and objectives of each such area will be 

17 achieved; and 

18 (C) how such funding supports the Na19 tional Drug Control Strategy; and 

20 (3) the amount of HIDTA funds used to inves21 tigate and prosecute organizations and individuals 

22 trafficking in each major illicit drug, as identified by 

23 the Director, in the prior calendar year, and a de24 scription of how those funds were used. 


sradovich on DSK3GMQ082PROD with BILLS
148 

HR 5925 RFS 

1 (k) HIDTA ANNUAL EVALUATION REPORT.—As 

2 part of each report submitted pursuant to section 1006(a) 

3 of title 31, United States Code, as added by section 2(c), 

4 the Director shall include, for each designated high inten5 sity drug trafficking area, a report that— 

6 (1) describes— 

7 (A) the specific purposes for the high in8 tensity drug trafficking area; and 

9 (B) the specific long-term and short-term 

10 goals and objectives for the high intensity drug 

11 trafficking area; 

12 (2) includes an evaluation of the performance of 

13 the high intensity drug trafficking area in accom14 plishing the specific long-term and short-term goals 

15 and objectives identified under subparagraph (1)(B); 

16 (3) assesses the number and operation of all 

17 federally funded drug enforcement task forces within 

18 such high intensity drug trafficking area; 

19 (4) describes— 

20 (A) each Federal, State, local, and Tribal 

21 drug enforcement task force operating in such 

22 high intensity drug trafficking area; 

23 (B) how such task forces coordinate with 

24 each other, with any high intensity drug traf25 ficking area task force, and with investigations 


sradovich on DSK3GMQ082PROD with BILLS
149 

HR 5925 RFS 

1 receiving funds from the Organized Crime and 

2 Drug Enforcement Task Force; 

3 (C) what steps, if any, each such task 

4 force takes to share information regarding drug 

5 trafficking and drug production with other fed6 erally funded drug enforcement task forces in 

7 the high intensity drug trafficking area; 

8 (D) the role of the high intensity drug 

9 trafficking area in coordinating the sharing of 

10 such information among task forces; 

11 (E) the nature and extent of cooperation 

12 by each Federal, State, local, and Tribal partic13 ipant in ensuring that such information is 

14 shared among law enforcement agencies and 

15 with the high intensity drug trafficking area; 

16 (F) the nature and extent to which infor17 mation sharing and enforcement activities are 

18 coordinated with joint terrorism task forces in 

19 the high intensity drug trafficking area; and 

20 (G) any recommendations for measures 

21 needed to ensure that task force resources are 

22 utilized efficiently and effectively to reduce the 

23 availability of illegal drugs in the high intensity 

24 drug trafficking areas; and 


sradovich on DSK3GMQ082PROD with BILLS
150 

HR 5925 RFS 

1 (5) in consultation with the Director of Na2 tional Intelligence— 

3 (A) evaluates existing and planned law en4 forcement intelligence systems supported by 

5 such high intensity drug trafficking area, or 

6 utilized by task forces receiving any funding 

7 under the Program, including the extent to 

8 which such systems ensure access and avail9 ability of law enforcement intelligence to Fed10 eral, State, local, and Tribal law enforcement 

11 agencies within the high intensity drug traf12 ficking area and outside of such area; 

13 (B) evaluates the extent to which Federal, 

14 State, local, and Tribal law enforcement agen15 cies participating in each high intensity drug 

16 trafficking area are sharing law enforcement in17 telligence information to assess current drug 

18 trafficking threats and design appropriate en19 forcement strategies; and 

20 (C) identifies the measures needed to im21 prove effective sharing of information and law 

22 enforcement intelligence regarding drug traf23 ficking and drug production among Federal, 

24 State, local, and Tribal law enforcement partici25 pating in a high intensity drug trafficking area, 


sradovich on DSK3GMQ082PROD with BILLS
151 

HR 5925 RFS 

1 and between such agencies and similar agencies 

2 outside the high intensity drug trafficking area. 

3 (l) COORDINATION OF LAW ENFORCEMENT INTEL4 LIGENCE SHARING WITH ORGANIZED CRIME DRUG EN5 FORCEMENT TASK FORCE PROGRAM.— 

6 (1) DRUG ENFORCEMENT INTELLIGENCE SHAR7 ING.—The Director, in consultation with the Attor8 ney General, shall ensure that any drug enforcement 

9 intelligence obtained by the Intelligence Support 

10 Center for each high intensity drug trafficking area 

11 is shared, on a timely basis, with the drug intel12 ligence fusion center operated by the Organized 

13 Crime Drug Enforcement Task Force of the Depart14 ment of Justice. 

15 (2) CERTIFICATION.—Before the Director 

16 awards any funds to a high intensity drug traf17 ficking area, the Director shall certify that the law 

18 enforcement entities participating in that HIDTA 

19 are providing laboratory seizure data to the national 

20 clandestine laboratory database at the El Paso Intel21 ligence Center. 

22 (m) AUTHORIZATION OF APPROPRIATIONS.—There is 

23 authorized to be appropriated to the Office to carry out 

24 this section $280 million for each fiscal years 2019 

25 through 2023. 


sradovich on DSK3GMQ082PROD with BILLS
152 

HR 5925 RFS 

1 (n) SPECIFIC PURPOSES.— 

2 (1) IN GENERAL.—The Director shall ensure 

3 that, of the amounts appropriated for a fiscal year 

4 for the Program, at least 2.5 percent is used in high 

5 intensity drug trafficking areas with severe neigh6 borhood safety and illegal drug distribution prob7 lems. 

8 (2) REQUIRED USES.—The funds used under 

9 paragraph (1) shall be used to ensure the safety of 

10 neighborhoods and the protection of communities, 

11 including the prevention of the intimidation of wit12 nesses of illegal drug distribution and related activi13 ties and the establishment of or support for pro14 grams that provide protection or assistance to wit15 nesses in court proceedings. 

16 (3) BEST PRACTICE MODELS.—The Director 

17 shall work with the HIDTAs to develop and main18 tain best practice models to assist State, local, and 

19 Tribal governments in addressing witness safety, re20 location, financial and housing assistance, or any 

21 other services related to witness protection or assist22 ance in cases of illegal drug distribution and related 

23 activities. The Director shall ensure dissemination of 

24 the best practice models to each HIDTA. 


sradovich on DSK3GMQ082PROD with BILLS
153 

HR 5925 RFS 

1 SEC. 4. OPIOID CRISIS RESPONSE. 

2 (a) EMERGING THREAT DESIGNATION.—The Direc3 tor shall designate opioids and opioid analogues as emerg4 ing drug threats, in accordance with section 1009 of title 

5 31, United States Code, as added by section 2(c). 

6 (b) OPIOID RESPONSE PLAN.— 

7 (1) ISSUANCE.—Not later than 60 days after 

8 the date of the enactment of this Act, the Director 

9 shall publish, make publicly available, and notify the 

10 President and the appropriate congressional commit11 tees of, the plan required under section 1009 of title 

12 31, United States Code, as added by section 2(c), to 

13 be designated as the ‘‘National Opioid Crisis Re14 sponse Plan’’. 

15 (2) CONTENTS.—The Director shall ensure the 

16 plan establishes measurable goals, including reduc17 ing fatal and non-fatal overdoses, and includes the 

18 following: 

19 (A) An initiative to ensure the United 

20 States mail is effectively screened to prevent il21 licit drugs from entering the United States, in22 cluding— 

23 (i) designating the United States 

24 Postal Service as a National Drug Control 

25 Program Agency; 


sradovich on DSK3GMQ082PROD with BILLS
154 

HR 5925 RFS 

1 (ii) directing the United States Postal 

2 Service and any other related National 

3 Drug Control Program Agency to take any 

4 appropriate actions necessary to reduce the 

5 amount of illicit drugs entering the coun6 try; and 

7 (iii) developing an international co8 ordination plan, in consultation with the 

9 National Drug Control Program Agencies 

10 and in accordance with section 1010 of 

11 such title 31, United States Code, as 

12 added by section 2(c), to include efforts to 

13 address international drug control initia14 tives and strengthen bilateral and multilat15 eral strategies to reduce illicit drugs and 

16 precursor chemicals from entering the 

17 United States through international mail 

18 or across land borders or ports of entry. 

19 (B) Support for universal adoption of evi20 dence-based prescribing guidelines, including— 

21 (i) establishing a task force to supple22 ment existing prescribing guidelines with 

23 evidence-based standards and to facilitate, 

24 coordinate, and, as appropriate, conduct 

25 research to inform such guidelines; 


sradovich on DSK3GMQ082PROD with BILLS
155 

HR 5925 RFS 

1 (ii) encouraging the adoption of evi2 dence-based prescribing guidelines by each 

3 relevant agency, State and local govern4 ments, and private sector organizations; 

5 (iii) issuing guidance to National 

6 Drug Control Program Agencies to, as ap7 propriate, revise regulations to ensure pro8 fessionals have effective continuing edu9 cation requirements; and 

10 (iv) disseminating and encouraging 

11 the adoption of best practices and evi12 dence-based guidelines for effective pre13 scribing practices. 

14 (C) A program to monitor the prescription 

15 drug market and illicit drug market for changes 

16 in trends relevant to reducing the supply or de17 mand of such drugs. 

18 (D) An initiative to facilitate and coordi19 nate Federal, State and local government initia20 tives, studies, and pilot or demonstration pro21 grams designed to evaluate the benefits of drug 

22 courts and related programs that reduce sub23 stance use prevalence. 

24 (E) A program, developed in coordination 

25 with the private sector, to— 


sradovich on DSK3GMQ082PROD with BILLS
156 

HR 5925 RFS 

1 (i) facilitate the development of treat2 ment and abuse-deterrent products, in ac3 cordance with section 1010(c) of title 31, 

4 United States Code, as added by section 

5 2(c); and 

6 (ii) encourage the expansion of medi7 cation disposal programs and technology. 

8 (F) Initiatives to— 

9 (i) encourage the National Drug Con10 trol Program Agencies and the program 

11 established under section 1010(d) of title 

12 31, United States Code, as added by sec13 tion 2(c), to prioritize the development of 

14 sentencing standards or model codes for 

15 trafficking opioids and opioid analogues; 

16 and 

17 (ii) to advise States on establishing 

18 laws and policies to address opioid issues 

19 based on the recommendations developed 

20 and set forth by the President’s Commis21 sion on Combating Drug Addiction and the 

22 Opioid Crisis. 

23 (G) A program to identify successful col24 lege recovery programs, including sober housing 

25 programs that provide a shared living residence 


sradovich on DSK3GMQ082PROD with BILLS
157 

HR 5925 RFS 

1 free of alcohol or illicit drug use for individuals 

2 recovering from drug or alcohol addiction and 

3 substance use disorders, on college campuses 

4 and disseminate best practices to Colleges and 

5 Universities to increase the number and capac6 ity of such programs. 

7 (H) Convening working groups, consisting 

8 of the appropriate National Drug Control Pro9 gram Agencies, State, local and Tribal govern10 ments, and other appropriate stakeholders, es11 tablished in accordance with section 1010 of 

12 title 31, United States Code, as added by sec13 tion 2(c)— 

14 (i) to support Prescription Drug Mon15 itoring Programs by— 

16 (I) facilitating the sharing and 

17 interoperability of program data 

18 among States and Federal prescrip19 tion drug monitoring programs; 

20 (II) assisting States in increasing 

21 utilization of such programs; 

22 (III) facilitating efforts to incor23 porate available overdose and 

24 naloxone deployment data into such 

25 programs; 


sradovich on DSK3GMQ082PROD with BILLS
158 

HR 5925 RFS 

1 (IV) evaluating barriers to inte2 grating program data with electronic 

3 health records; and 

4 (V) offering recommendations to 

5 address identified barriers; and 

6 (ii) to develop standards, and encour7 age the use of such standards, for the col8 lection of data necessary to understand 

9 and monitor the opioid crisis, including— 

10 (I) State medical examiner re11 ports on deaths caused by overdoses 

12 and related statistical data; and 

13 (II) first responder opioid intoxi14 cation incidents. 

15 (I) Research initiatives, to be initiated not 

16 later than 30 days after the issuance of the 

17 plan, to evaluate the uses and barriers to use 

18 of and the effects of improving the following 

19 programs: 

20 (i) Medication Assisted Treatment. 

21 (ii) Data collection systems used to 

22 confirm opioid use by individuals who have 

23 been arrested or hospitalized. 

24 (J) A requirement for an Advisory Com25 mittee on Substance Use Disorder Treatment 


sradovich on DSK3GMQ082PROD with BILLS
159 

HR 5925 RFS 

1 Standards, to be established not later than 120 

2 days after the issuance of the plan, to promul3 gate model evidence-based standards for sub4 stance use disorder treatment and recovery fa5 cilities which— 

6 (i) shall be chaired by the Director; 

7 (ii) shall include as members of the 

8 advisory committee representatives of the 

9 relevant National Drug Control Program 

10 Agencies; 

11 (iii) may include as members of the 

12 advisory committee government regulators, 

13 State representatives, consumer represent14 atives, substance use disorder treatment 

15 providers, recovery residence owners and 

16 operators, and purchasers of substance use 

17 disorder treatments; and 

18 (iv) shall ensure such model standards 

19 are promulgated no later than 2 years 

20 after the date of the issuance of the plan. 

21 (c) RECOMMENDATIONS.—Not later than 1 year after 

22 the date of the enactment of this Act, the Director shall 

23 submit to the appropriate congressional committees a re24 port on the results of the initiatives conducted under subVerDate Sep 11 2014 23:16 Jun 21, 2018 Jkt 079200 PO 00000 Frm 00159 Fmt 6652 Sfmt 6201 E:\BILLS\H5925.RFS H5925

sradovich on DSK3GMQ082PROD with BILLS
160 

HR 5925 RFS 

1 section (b)(2)(I) and may include recommendations based 

2 on such results. 

3 (d) GRANT REPORT TO CONGRESS.—Not later than 

4 1 year after the date of the enactment of this Act, the 

5 Director shall submit to the appropriate congressional 

6 committees an assessment on the feasibility of block 

7 grants of Federal funding to States. 

8 SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION. 

9 (a) INAPPLICABILITY TO CERTAIN PROGRAMS.—This 

10 Act, and the amendments made by this Act, shall not 

11 apply to the National Intelligence Program and the Mili12 tary Intelligence Program, unless such program or an ele13 ment of such program is designated as a National Drug 

14 Control Program— 

15 (1) by the President; or 

16 (2) jointly by— 

17 (A) in the case of the National Intelligence 

18 Program, the Director and the Director of Na19 tional Intelligence; or 

20 (B) in the case of the Military Intelligence 

21 Program, the Director, the Director of National 

22 Intelligence, and the Secretary of Defense. 

23 (b) CLASSIFIED INFORMATION.—Any contents of any 

24 report required under this Act, or the amendments made 

25 by this Act, that involve information properly classified 


sradovich on DSK3GMQ082PROD with BILLS
161 

HR 5925 RFS 

1 under criteria established by an Executive order shall be 

2 presented to Congress separately from the rest of such re3 port. 

4 (c) USE OF EXISTING RESOURCES.—To the extent 

5 practicable, the Director and the head of each agency shall 

6 use existing procedures and systems to carry out agency 

7 requirements under this Act, and the amendments made 

8 by this Act. 

9 SEC. 6. GAO AUDIT AND REPORTS. 

10 Not later than 3 and 6 years after the date of the 

11 enactment of this Act, the Comptroller General shall— 

12 (1) conduct an audit relating to the programs 

13 and operations of— 

14 (A) the Office; and 

15 (B) certain programs within the Office, in16 cluding— 

17 (i) the High Intensity Drug Traf18 ficking Areas Program; 

19 (ii) the Drug-Free Communities Pro20 gram; and 

21 (iii) the campaign under section 

22 1009(d) of title 31, as added by section 

23 2(c); and 


sradovich on DSK3GMQ082PROD with BILLS
162 

HR 5925 RFS 

1 (2) submit to the Director and the appropriate 

2 congressional committees a report containing an 

3 evaluation of and recommendations on the— 

4 (A) policies and activities of the programs 

5 and operations subject to the audit; 

6 (B) economy, efficiency, and effectiveness 

7 in the administration of the reviewed programs 

8 and operations; and 

9 (C) policy or management changes needed 

10 to prevent and detect fraud and abuse in such 

11 programs and operations. 

12 SEC. 7. REPEALS. 

13 (a) REPEALS TO THE LAW.—The following provisions 

14 are repealed: 

15 (1) The Office of National Drug Control Policy 

16 Reauthorization Act of 1998 (Public Law 105–277; 

17 21 U.S.C. 1701 et seq.). 

18 (2) Chapter 2 of the National Narcotics Lead19 ership Act of 1988 (Public Law 100–690; 21 U.S.C. 

20 1501 et seq.). 

21 (3) Section 203 of the Office of National Drug 

22 Control Policy Reauthorization Act of 2006 (Public 

23 Law 109–469; 21 U.S.C. 1708a). 


sradovich on DSK3GMQ082PROD with BILLS
163 

HR 5925 RFS 

1 (4) Section 1105 of the Office of National Drug 

2 Control Policy Reauthorization Act of 2006 (Public 

3 Law 109–469; 21 U.S.C. 1701 note). 

4 (5) Section 1110 of Office of National Drug 

5 Control Policy Reauthorization Act of 2006 (Public 

6 Law 109–469; 21 U.S.C. 1705 note). 

7 (6) Section 1110A of the Office of National 

8 Drug Control Policy Reauthorization Act of 2006 

9 (Public Law 109–469; 21 U.S.C. 1705 note). 

10 (7) Section 4 of Public Law 107–82 (21 U.S.C. 

11 1521 note). 

12 (b) EFFECT ON THE CODE.—The Law Revision 

13 Counsel shall ensure that the website and any other publi14 cation issued after the date of the enactment of this Act 

15 for the Office of the Law Revision Counsel shows that the 

16 laws reflected in subchapter II of chapter 20 and chapter 

17 22 of nonpositive law title 21 of the United States Code 

18 have been repealed. 

19 SEC. 8. DEFINITIONS. 

20 In this Act, the terms ‘‘agency’’, ‘‘appropriate con21 gressional committees’’, ‘‘Director’’, ‘‘drug’’, ‘‘emerging 

22 drug threat’’, ‘‘illicit drug use’’, ‘‘illicit drugs’’, ‘‘National 

23 Drug Control Program Agencies’’, and ‘‘Office’’ have the 


sradovich on DSK3GMQ082PROD with BILLS
164 

HR 5925 RFS 

1 meaning given those terms in section 1001 of title 31, 

2 United States Code, as added by section 2(c). 

Passed the House of Representatives June 20, 2018. 

Attest: KAREN L. HAAS, 

Clerk. 


sradovich on DSK3GMQ082PROD with BILLS